US20180116972A1 - Lipid based nanocarrier compositions loaded with metal nanoparticles and therapeutic agent - Google Patents
Lipid based nanocarrier compositions loaded with metal nanoparticles and therapeutic agent Download PDFInfo
- Publication number
- US20180116972A1 US20180116972A1 US15/567,628 US201615567628A US2018116972A1 US 20180116972 A1 US20180116972 A1 US 20180116972A1 US 201615567628 A US201615567628 A US 201615567628A US 2018116972 A1 US2018116972 A1 US 2018116972A1
- Authority
- US
- United States
- Prior art keywords
- group
- lipid
- branched
- linear
- chain
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 64
- 239000002539 nanocarrier Substances 0.000 title claims abstract description 57
- 150000002632 lipids Chemical class 0.000 title claims abstract description 56
- 239000002082 metal nanoparticle Substances 0.000 title claims abstract description 31
- 239000003814 drug Substances 0.000 title claims abstract description 29
- 229940124597 therapeutic agent Drugs 0.000 title claims abstract description 23
- 239000003795 chemical substances by application Substances 0.000 claims abstract description 19
- 230000001413 cellular effect Effects 0.000 claims abstract description 6
- 230000008685 targeting Effects 0.000 claims abstract description 5
- 230000030570 cellular localization Effects 0.000 claims abstract description 3
- 150000001875 compounds Chemical class 0.000 claims description 29
- 125000002252 acyl group Chemical group 0.000 claims description 23
- 125000004435 hydrogen atom Chemical class [H]* 0.000 claims description 23
- 125000000217 alkyl group Chemical group 0.000 claims description 22
- 229910052739 hydrogen Inorganic materials 0.000 claims description 21
- 239000001257 hydrogen Substances 0.000 claims description 21
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 19
- 125000004433 nitrogen atom Chemical group N* 0.000 claims description 18
- 125000001072 heteroaryl group Chemical group 0.000 claims description 17
- 239000000243 solution Substances 0.000 claims description 16
- 125000001183 hydrocarbyl group Chemical group 0.000 claims description 15
- DRTQHJPVMGBUCF-XVFCMESISA-N Uridine Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C=C1 DRTQHJPVMGBUCF-XVFCMESISA-N 0.000 claims description 14
- 125000001570 methylene group Chemical group [H]C([H])([*:1])[*:2] 0.000 claims description 13
- -1 hydroxy, amino Chemical group 0.000 claims description 12
- 125000004430 oxygen atom Chemical group O* 0.000 claims description 11
- 229920006395 saturated elastomer Polymers 0.000 claims description 11
- CZPWVGJYEJSRLH-UHFFFAOYSA-N Pyrimidine Chemical group C1=CN=CN=C1 CZPWVGJYEJSRLH-UHFFFAOYSA-N 0.000 claims description 9
- 238000003756 stirring Methods 0.000 claims description 9
- KDCGOANMDULRCW-UHFFFAOYSA-N Purine Natural products N1=CNC2=NC=NC2=C1 KDCGOANMDULRCW-UHFFFAOYSA-N 0.000 claims description 8
- ISAKRJDGNUQOIC-UHFFFAOYSA-N Uracil Chemical group O=C1C=CNC(=O)N1 ISAKRJDGNUQOIC-UHFFFAOYSA-N 0.000 claims description 8
- RWQNBRDOKXIBIV-UHFFFAOYSA-N thymine Chemical group CC1=CNC(=O)NC1=O RWQNBRDOKXIBIV-UHFFFAOYSA-N 0.000 claims description 8
- DRTQHJPVMGBUCF-PSQAKQOGSA-N beta-L-uridine Natural products O[C@H]1[C@@H](O)[C@H](CO)O[C@@H]1N1C(=O)NC(=O)C=C1 DRTQHJPVMGBUCF-PSQAKQOGSA-N 0.000 claims description 7
- 125000005740 oxycarbonyl group Chemical group [*:1]OC([*:2])=O 0.000 claims description 7
- DRTQHJPVMGBUCF-UHFFFAOYSA-N uracil arabinoside Natural products OC1C(O)C(CO)OC1N1C(=O)NC(=O)C=C1 DRTQHJPVMGBUCF-UHFFFAOYSA-N 0.000 claims description 7
- 229940045145 uridine Drugs 0.000 claims description 7
- IQFYYKKMVGJFEH-XLPZGREQSA-N Thymidine Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](O)C1 IQFYYKKMVGJFEH-XLPZGREQSA-N 0.000 claims description 6
- 239000003960 organic solvent Substances 0.000 claims description 6
- 125000002467 phosphate group Chemical group [H]OP(=O)(O[H])O[*] 0.000 claims description 6
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 claims description 5
- ABLZXFCXXLZCGV-UHFFFAOYSA-N Phosphorous acid Chemical group OP(O)=O ABLZXFCXXLZCGV-UHFFFAOYSA-N 0.000 claims description 5
- 125000001424 substituent group Chemical group 0.000 claims description 5
- WWUZIQQURGPMPG-UHFFFAOYSA-N (-)-D-erythro-Sphingosine Natural products CCCCCCCCCCCCCC=CC(O)C(N)CO WWUZIQQURGPMPG-UHFFFAOYSA-N 0.000 claims description 4
- 125000006577 C1-C6 hydroxyalkyl group Chemical group 0.000 claims description 4
- KXDHJXZQYSOELW-UHFFFAOYSA-M Carbamate Chemical compound NC([O-])=O KXDHJXZQYSOELW-UHFFFAOYSA-M 0.000 claims description 4
- BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 claims description 4
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 4
- UQSXHKLRYXJYBZ-UHFFFAOYSA-N Iron oxide Chemical compound [Fe]=O UQSXHKLRYXJYBZ-UHFFFAOYSA-N 0.000 claims description 4
- 229910019142 PO4 Inorganic materials 0.000 claims description 4
- 229930182558 Sterol Natural products 0.000 claims description 4
- GNVMUORYQLCPJZ-UHFFFAOYSA-M Thiocarbamate Chemical compound NC([S-])=O GNVMUORYQLCPJZ-UHFFFAOYSA-M 0.000 claims description 4
- 230000000879 anti-atherosclerotic effect Effects 0.000 claims description 4
- 239000012736 aqueous medium Substances 0.000 claims description 4
- 125000004432 carbon atom Chemical group C* 0.000 claims description 4
- 125000001549 ceramide group Chemical group 0.000 claims description 4
- 125000004122 cyclic group Chemical group 0.000 claims description 4
- 150000001982 diacylglycerols Chemical class 0.000 claims description 4
- 239000000539 dimer Substances 0.000 claims description 4
- 239000002184 metal Substances 0.000 claims description 4
- 229910052751 metal Inorganic materials 0.000 claims description 4
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 claims description 4
- 239000010452 phosphate Substances 0.000 claims description 4
- WTJKGGKOPKCXLL-RRHRGVEJSA-N phosphatidylcholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCC=CCCCCCCCC WTJKGGKOPKCXLL-RRHRGVEJSA-N 0.000 claims description 4
- UEZVMMHDMIWARA-UHFFFAOYSA-M phosphonate Chemical compound [O-]P(=O)=O UEZVMMHDMIWARA-UHFFFAOYSA-M 0.000 claims description 4
- XYFCBTPGUUZFHI-UHFFFAOYSA-O phosphonium Chemical compound [PH4+] XYFCBTPGUUZFHI-UHFFFAOYSA-O 0.000 claims description 4
- 125000000561 purinyl group Chemical group N1=C(N=C2N=CNC2=C1)* 0.000 claims description 4
- WWUZIQQURGPMPG-KRWOKUGFSA-N sphingosine Chemical compound CCCCCCCCCCCCC\C=C\[C@@H](O)[C@@H](N)CO WWUZIQQURGPMPG-KRWOKUGFSA-N 0.000 claims description 4
- 235000003702 sterols Nutrition 0.000 claims description 4
- 229910052717 sulfur Inorganic materials 0.000 claims description 4
- 125000004434 sulfur atom Chemical group 0.000 claims description 4
- RYYWUUFWQRZTIU-UHFFFAOYSA-K thiophosphate Chemical compound [O-]P([O-])([O-])=S RYYWUUFWQRZTIU-UHFFFAOYSA-K 0.000 claims description 4
- 229940113082 thymine Drugs 0.000 claims description 4
- DWRXFEITVBNRMK-UHFFFAOYSA-N Beta-D-1-Arabinofuranosylthymine Natural products O=C1NC(=O)C(C)=CN1C1C(O)C(O)C(CO)O1 DWRXFEITVBNRMK-UHFFFAOYSA-N 0.000 claims description 3
- 230000000259 anti-tumor effect Effects 0.000 claims description 3
- IQFYYKKMVGJFEH-UHFFFAOYSA-N beta-L-thymidine Natural products O=C1NC(=O)C(C)=CN1C1OC(CO)C(O)C1 IQFYYKKMVGJFEH-UHFFFAOYSA-N 0.000 claims description 3
- 150000002148 esters Chemical class 0.000 claims description 3
- 238000001704 evaporation Methods 0.000 claims description 3
- 238000004519 manufacturing process Methods 0.000 claims description 3
- 229910044991 metal oxide Inorganic materials 0.000 claims description 3
- 150000004706 metal oxides Chemical class 0.000 claims description 3
- 102000004169 proteins and genes Human genes 0.000 claims description 3
- 108090000623 proteins and genes Proteins 0.000 claims description 3
- 229940104230 thymidine Drugs 0.000 claims description 3
- 102000015636 Oligopeptides Human genes 0.000 claims description 2
- 108010038807 Oligopeptides Proteins 0.000 claims description 2
- 239000000730 antalgic agent Substances 0.000 claims description 2
- 239000000427 antigen Substances 0.000 claims description 2
- 102000036639 antigens Human genes 0.000 claims description 2
- 108091007433 antigens Proteins 0.000 claims description 2
- 239000000739 antihistaminic agent Substances 0.000 claims description 2
- 229940125715 antihistaminic agent Drugs 0.000 claims description 2
- 239000002220 antihypertensive agent Substances 0.000 claims description 2
- 239000004599 antimicrobial Substances 0.000 claims description 2
- 239000007864 aqueous solution Substances 0.000 claims description 2
- 230000003115 biocidal effect Effects 0.000 claims description 2
- 229940124630 bronchodilator Drugs 0.000 claims description 2
- 239000000168 bronchodilator agent Substances 0.000 claims description 2
- 210000000748 cardiovascular system Anatomy 0.000 claims description 2
- 210000003169 central nervous system Anatomy 0.000 claims description 2
- 150000004770 chalcogenides Chemical class 0.000 claims description 2
- 125000003374 diacylglycerol group Chemical group 0.000 claims description 2
- 239000003937 drug carrier Substances 0.000 claims description 2
- 239000012634 fragment Substances 0.000 claims description 2
- 229910001092 metal group alloy Inorganic materials 0.000 claims description 2
- 150000002739 metals Chemical class 0.000 claims description 2
- 108020004707 nucleic acids Proteins 0.000 claims description 2
- 102000039446 nucleic acids Human genes 0.000 claims description 2
- 150000007523 nucleic acids Chemical class 0.000 claims description 2
- 239000008194 pharmaceutical composition Substances 0.000 claims description 2
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 2
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 2
- 210000000130 stem cell Anatomy 0.000 claims description 2
- GVJHHUAWPYXKBD-IEOSBIPESA-N α-tocopherol Chemical compound OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-IEOSBIPESA-N 0.000 description 34
- 229940031182 nanoparticles iron oxide Drugs 0.000 description 29
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 26
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 22
- 238000009826 distribution Methods 0.000 description 20
- 238000002296 dynamic light scattering Methods 0.000 description 20
- 239000002105 nanoparticle Substances 0.000 description 18
- 238000002360 preparation method Methods 0.000 description 18
- 239000011550 stock solution Substances 0.000 description 17
- 229940087168 alpha tocopherol Drugs 0.000 description 14
- 229960000984 tocofersolan Drugs 0.000 description 14
- 239000002076 α-tocopherol Substances 0.000 description 14
- 235000004835 α-tocopherol Nutrition 0.000 description 14
- 239000011521 glass Substances 0.000 description 12
- 102000005666 Apolipoprotein A-I Human genes 0.000 description 10
- 108010059886 Apolipoprotein A-I Proteins 0.000 description 10
- 210000004623 platelet-rich plasma Anatomy 0.000 description 10
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 9
- KAQKFAOMNZTLHT-OZUDYXHBSA-N prostaglandin I2 Chemical compound O1\C(=C/CCCC(O)=O)C[C@@H]2[C@@H](/C=C/[C@@H](O)CCCCC)[C@H](O)C[C@@H]21 KAQKFAOMNZTLHT-OZUDYXHBSA-N 0.000 description 9
- XTWYTFMLZFPYCI-KQYNXXCUSA-N 5'-adenylphosphoric acid Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](COP(O)(=O)OP(O)(O)=O)[C@@H](O)[C@H]1O XTWYTFMLZFPYCI-KQYNXXCUSA-N 0.000 description 8
- 101000862089 Clarkia lewisii Glucose-6-phosphate isomerase, cytosolic 1A Proteins 0.000 description 8
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 8
- 239000008346 aqueous phase Substances 0.000 description 7
- 238000001514 detection method Methods 0.000 description 7
- 230000002209 hydrophobic effect Effects 0.000 description 7
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 6
- 239000012901 Milli-Q water Substances 0.000 description 6
- 239000013058 crude material Substances 0.000 description 6
- 239000012074 organic phase Substances 0.000 description 6
- 108010063955 thrombin receptor peptide (42-47) Proteins 0.000 description 6
- 229940079593 drug Drugs 0.000 description 5
- 238000004128 high performance liquid chromatography Methods 0.000 description 5
- 238000003384 imaging method Methods 0.000 description 5
- 238000002560 therapeutic procedure Methods 0.000 description 5
- HEWZVZIVELJPQZ-UHFFFAOYSA-N COC(C)(C)OC Chemical compound COC(C)(C)OC HEWZVZIVELJPQZ-UHFFFAOYSA-N 0.000 description 4
- AOJJSUZBOXZQNB-TZSSRYMLSA-N Doxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-TZSSRYMLSA-N 0.000 description 4
- 0 [1*]CC1C(C[3*])CC(B)C1C[2*] Chemical compound [1*]CC1C(C[3*])CC(B)C1C[2*] 0.000 description 4
- 239000000556 agonist Substances 0.000 description 4
- 238000004458 analytical method Methods 0.000 description 4
- 230000015572 biosynthetic process Effects 0.000 description 4
- 125000002091 cationic group Chemical group 0.000 description 4
- 238000005119 centrifugation Methods 0.000 description 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 4
- 238000002474 experimental method Methods 0.000 description 4
- 230000006870 function Effects 0.000 description 4
- 238000011534 incubation Methods 0.000 description 4
- 238000002595 magnetic resonance imaging Methods 0.000 description 4
- 238000000034 method Methods 0.000 description 4
- 238000012544 monitoring process Methods 0.000 description 4
- IGFXRKMLLMBKSA-UHFFFAOYSA-N purine Chemical compound N1=C[N]C2=NC=NC2=C1 IGFXRKMLLMBKSA-UHFFFAOYSA-N 0.000 description 4
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 3
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 3
- 238000013459 approach Methods 0.000 description 3
- 239000002872 contrast media Substances 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- KAQKFAOMNZTLHT-VVUHWYTRSA-N epoprostenol Chemical compound O1C(=CCCCC(O)=O)C[C@@H]2[C@@H](/C=C/[C@@H](O)CCCCC)[C@H](O)C[C@@H]21 KAQKFAOMNZTLHT-VVUHWYTRSA-N 0.000 description 3
- 239000000499 gel Substances 0.000 description 3
- RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Natural products C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 description 3
- XEEYBQQBJWHFJM-UHFFFAOYSA-N iron Substances [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 3
- WTFXARWRTYJXII-UHFFFAOYSA-N iron(2+);iron(3+);oxygen(2-) Chemical compound [O-2].[O-2].[O-2].[O-2].[Fe+2].[Fe+3].[Fe+3] WTFXARWRTYJXII-UHFFFAOYSA-N 0.000 description 3
- SZVJSHCCFOBDDC-UHFFFAOYSA-N iron(II,III) oxide Inorganic materials O=[Fe]O[Fe]O[Fe]=O SZVJSHCCFOBDDC-UHFFFAOYSA-N 0.000 description 3
- 238000011068 loading method Methods 0.000 description 3
- 239000013642 negative control Substances 0.000 description 3
- 239000008188 pellet Substances 0.000 description 3
- 239000002244 precipitate Substances 0.000 description 3
- 239000002096 quantum dot Substances 0.000 description 3
- 238000011084 recovery Methods 0.000 description 3
- 239000011734 sodium Substances 0.000 description 3
- 208000010110 spontaneous platelet aggregation Diseases 0.000 description 3
- 239000006228 supernatant Substances 0.000 description 3
- 239000000725 suspension Substances 0.000 description 3
- 229930003799 tocopherol Natural products 0.000 description 3
- 239000011732 tocopherol Substances 0.000 description 3
- 238000011282 treatment Methods 0.000 description 3
- SNKAWJBJQDLSFF-NVKMUCNASA-N 1,2-dioleoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCC\C=C/CCCCCCCC SNKAWJBJQDLSFF-NVKMUCNASA-N 0.000 description 2
- LRFVTYWOQMYALW-UHFFFAOYSA-N 9H-xanthine Chemical compound O=C1NC(=O)NC2=C1NC=N2 LRFVTYWOQMYALW-UHFFFAOYSA-N 0.000 description 2
- 101100297345 Caenorhabditis elegans pgl-2 gene Proteins 0.000 description 2
- SIKJAQJRHWYJAI-UHFFFAOYSA-N Indole Chemical compound C1=CC=C2NC=CC2=C1 SIKJAQJRHWYJAI-UHFFFAOYSA-N 0.000 description 2
- 239000005517 L01XE01 - Imatinib Substances 0.000 description 2
- LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 description 2
- 108091034117 Oligonucleotide Proteins 0.000 description 2
- KYQCOXFCLRTKLS-UHFFFAOYSA-N Pyrazine Chemical compound C1=CN=CC=N1 KYQCOXFCLRTKLS-UHFFFAOYSA-N 0.000 description 2
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 2
- KAESVJOAVNADME-UHFFFAOYSA-N Pyrrole Chemical compound C=1C=CNC=1 KAESVJOAVNADME-UHFFFAOYSA-N 0.000 description 2
- RBPWQIKZHBYIEY-PXCYNBOKSA-N [(2r)-2,3-bis[(z)-octadec-9-enoxy]propyl] 2-(trimethylazaniumyl)ethyl phosphate Chemical compound CCCCCCCC\C=C/CCCCCCCCOC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OCCCCCCCC\C=C/CCCCCCCC RBPWQIKZHBYIEY-PXCYNBOKSA-N 0.000 description 2
- 230000002776 aggregation Effects 0.000 description 2
- 238000004220 aggregation Methods 0.000 description 2
- 125000000129 anionic group Chemical group 0.000 description 2
- 230000002744 anti-aggregatory effect Effects 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 230000005540 biological transmission Effects 0.000 description 2
- UHYPYGJEEGLRJD-UHFFFAOYSA-N cadmium(2+);selenium(2-) Chemical compound [Se-2].[Cd+2] UHYPYGJEEGLRJD-UHFFFAOYSA-N 0.000 description 2
- RYYVLZVUVIJVGH-UHFFFAOYSA-N caffeine Chemical compound CN1C(=O)N(C)C(=O)C2=C1N=CN2C RYYVLZVUVIJVGH-UHFFFAOYSA-N 0.000 description 2
- DQLATGHUWYMOKM-UHFFFAOYSA-L cisplatin Chemical compound N[Pt](N)(Cl)Cl DQLATGHUWYMOKM-UHFFFAOYSA-L 0.000 description 2
- OPTASPLRGRRNAP-UHFFFAOYSA-N cytosine Chemical compound NC=1C=CNC(=O)N=1 OPTASPLRGRRNAP-UHFFFAOYSA-N 0.000 description 2
- GVJHHUAWPYXKBD-UHFFFAOYSA-N d-alpha-tocopherol Natural products OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000035475 disorder Diseases 0.000 description 2
- 238000012377 drug delivery Methods 0.000 description 2
- 238000005538 encapsulation Methods 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 2
- 150000004665 fatty acids Chemical class 0.000 description 2
- SDUQYLNIPVEERB-QPPQHZFASA-N gemcitabine Chemical compound O=C1N=C(N)C=CN1[C@H]1C(F)(F)[C@H](O)[C@@H](CO)O1 SDUQYLNIPVEERB-QPPQHZFASA-N 0.000 description 2
- 229910052737 gold Inorganic materials 0.000 description 2
- 239000010931 gold Substances 0.000 description 2
- UYTPUPDQBNUYGX-UHFFFAOYSA-N guanine Chemical compound O=C1NC(N)=NC2=C1N=CN2 UYTPUPDQBNUYGX-UHFFFAOYSA-N 0.000 description 2
- FDGQSTZJBFJUBT-UHFFFAOYSA-N hypoxanthine Chemical compound O=C1NC=NC2=C1NC=N2 FDGQSTZJBFJUBT-UHFFFAOYSA-N 0.000 description 2
- KTUFNOKKBVMGRW-UHFFFAOYSA-N imatinib Chemical compound C1CN(C)CCN1CC1=CC=C(C(=O)NC=2C=C(NC=3N=C(C=CN=3)C=3C=NC=CC=3)C(C)=CC=2)C=C1 KTUFNOKKBVMGRW-UHFFFAOYSA-N 0.000 description 2
- 238000000338 in vitro Methods 0.000 description 2
- 230000003993 interaction Effects 0.000 description 2
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 2
- 230000007935 neutral effect Effects 0.000 description 2
- 239000002245 particle Substances 0.000 description 2
- 239000012071 phase Substances 0.000 description 2
- 210000002381 plasma Anatomy 0.000 description 2
- 238000011002 quantification Methods 0.000 description 2
- 238000000679 relaxometry Methods 0.000 description 2
- 230000035945 sensitivity Effects 0.000 description 2
- 238000000926 separation method Methods 0.000 description 2
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 2
- 230000006641 stabilisation Effects 0.000 description 2
- RMMXLENWKUUMAY-UHFFFAOYSA-N telmisartan Chemical compound CCCC1=NC2=C(C)C=C(C=3N(C4=CC=CC=C4N=3)C)C=C2N1CC(C=C1)=CC=C1C1=CC=CC=C1C(O)=O RMMXLENWKUUMAY-UHFFFAOYSA-N 0.000 description 2
- YAPQBXQYLJRXSA-UHFFFAOYSA-N theobromine Chemical compound CN1C(=O)NC(=O)C2=C1N=CN2C YAPQBXQYLJRXSA-UHFFFAOYSA-N 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 150000003573 thiols Chemical class 0.000 description 2
- 235000010384 tocopherol Nutrition 0.000 description 2
- 229960001295 tocopherol Drugs 0.000 description 2
- 150000003852 triazoles Chemical class 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- 229910000859 α-Fe Inorganic materials 0.000 description 2
- NGGMYCMLYOUNGM-UHFFFAOYSA-N (-)-fumagillin Natural products O1C(CC=C(C)C)C1(C)C1C(OC)C(OC(=O)C=CC=CC=CC=CC(O)=O)CCC21CO2 NGGMYCMLYOUNGM-UHFFFAOYSA-N 0.000 description 1
- IANQTJSKSUMEQM-UHFFFAOYSA-N 1-benzofuran Chemical compound C1=CC=C2OC=CC2=C1 IANQTJSKSUMEQM-UHFFFAOYSA-N 0.000 description 1
- XNMYNYSCEJBRPZ-UHFFFAOYSA-N 2-[(3-butyl-1-isoquinolinyl)oxy]-N,N-dimethylethanamine Chemical compound C1=CC=C2C(OCCN(C)C)=NC(CCCC)=CC2=C1 XNMYNYSCEJBRPZ-UHFFFAOYSA-N 0.000 description 1
- HWEOXFSBSQIWSY-MRXNPFEDSA-N 3-[(6r)-6-[(4-chlorophenyl)sulfonylamino]-2-methyl-5,6,7,8-tetrahydronaphthalen-1-yl]propanoic acid Chemical compound N([C@H]1CC2=CC=C(C(=C2CC1)CCC(O)=O)C)S(=O)(=O)C1=CC=C(Cl)C=C1 HWEOXFSBSQIWSY-MRXNPFEDSA-N 0.000 description 1
- LOJNBPNACKZWAI-UHFFFAOYSA-N 3-nitro-1h-pyrrole Chemical compound [O-][N+](=O)C=1C=CNC=1 LOJNBPNACKZWAI-UHFFFAOYSA-N 0.000 description 1
- KYWCWBXGRWWINE-UHFFFAOYSA-N 4-methoxy-N1,N3-bis(3-pyridinylmethyl)benzene-1,3-dicarboxamide Chemical compound COC1=CC=C(C(=O)NCC=2C=NC=CC=2)C=C1C(=O)NCC1=CC=CN=C1 KYWCWBXGRWWINE-UHFFFAOYSA-N 0.000 description 1
- OZFPSOBLQZPIAV-UHFFFAOYSA-N 5-nitro-1h-indole Chemical compound [O-][N+](=O)C1=CC=C2NC=CC2=C1 OZFPSOBLQZPIAV-UHFFFAOYSA-N 0.000 description 1
- VYDWQPKRHOGLPA-UHFFFAOYSA-N 5-nitroimidazole Chemical compound [O-][N+](=O)C1=CN=CN1 VYDWQPKRHOGLPA-UHFFFAOYSA-N 0.000 description 1
- STQGQHZAVUOBTE-UHFFFAOYSA-N 7-Cyan-hept-2t-en-4,6-diinsaeure Natural products C1=2C(O)=C3C(=O)C=4C(OC)=CC=CC=4C(=O)C3=C(O)C=2CC(O)(C(C)=O)CC1OC1CC(N)C(O)C(C)O1 STQGQHZAVUOBTE-UHFFFAOYSA-N 0.000 description 1
- FUXVKZWTXQUGMW-FQEVSTJZSA-N 9-Aminocamptothecin Chemical compound C1=CC(N)=C2C=C(CN3C4=CC5=C(C3=O)COC(=O)[C@]5(O)CC)C4=NC2=C1 FUXVKZWTXQUGMW-FQEVSTJZSA-N 0.000 description 1
- 229930024421 Adenine Natural products 0.000 description 1
- GFFGJBXGBJISGV-UHFFFAOYSA-N Adenine Chemical compound NC1=NC=NC2=C1N=CN2 GFFGJBXGBJISGV-UHFFFAOYSA-N 0.000 description 1
- UXOWGYHJODZGMF-QORCZRPOSA-N Aliskiren Chemical compound COCCCOC1=CC(C[C@@H](C[C@H](N)[C@@H](O)C[C@@H](C(C)C)C(=O)NCC(C)(C)C(N)=O)C(C)C)=CC=C1OC UXOWGYHJODZGMF-QORCZRPOSA-N 0.000 description 1
- 201000001320 Atherosclerosis Diseases 0.000 description 1
- MLDQJTXFUGDVEO-UHFFFAOYSA-N BAY-43-9006 Chemical compound C1=NC(C(=O)NC)=CC(OC=2C=CC(NC(=O)NC=3C=C(C(Cl)=CC=3)C(F)(F)F)=CC=2)=C1 MLDQJTXFUGDVEO-UHFFFAOYSA-N 0.000 description 1
- 102100028990 C-X-C chemokine receptor type 3 Human genes 0.000 description 1
- 239000002083 C09CA01 - Losartan Substances 0.000 description 1
- 239000002947 C09CA04 - Irbesartan Substances 0.000 description 1
- 239000005537 C09CA07 - Telmisartan Substances 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical group [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- 229910018979 CoPt Inorganic materials 0.000 description 1
- WEAHRLBPCANXCN-UHFFFAOYSA-N Daunomycin Natural products CCC1(O)CC(OC2CC(N)C(O)C(C)O2)c3cc4C(=O)c5c(OC)cccc5C(=O)c4c(O)c3C1 WEAHRLBPCANXCN-UHFFFAOYSA-N 0.000 description 1
- 206010061818 Disease progression Diseases 0.000 description 1
- 208000030453 Drug-Related Side Effects and Adverse reaction Diseases 0.000 description 1
- 229910002546 FeCo Inorganic materials 0.000 description 1
- 229910005335 FePt Inorganic materials 0.000 description 1
- GHASVSINZRGABV-UHFFFAOYSA-N Fluorouracil Chemical compound FC1=CNC(=O)NC1=O GHASVSINZRGABV-UHFFFAOYSA-N 0.000 description 1
- BDAGIHXWWSANSR-UHFFFAOYSA-N Formic acid Chemical compound OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 1
- YLQBMQCUIZJEEH-UHFFFAOYSA-N Furan Chemical compound C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 1
- 241000282414 Homo sapiens Species 0.000 description 1
- 101000916050 Homo sapiens C-X-C chemokine receptor type 3 Proteins 0.000 description 1
- VSNHCAURESNICA-UHFFFAOYSA-N Hydroxyurea Chemical compound NC(=O)NO VSNHCAURESNICA-UHFFFAOYSA-N 0.000 description 1
- UGQMRVRMYYASKQ-UHFFFAOYSA-N Hypoxanthine nucleoside Natural products OC1C(O)C(CO)OC1N1C(NC=NC2=O)=C2N=C1 UGQMRVRMYYASKQ-UHFFFAOYSA-N 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 108090000174 Interleukin-10 Proteins 0.000 description 1
- 102000003814 Interleukin-10 Human genes 0.000 description 1
- LPHGQDQBBGAPDZ-UHFFFAOYSA-N Isocaffeine Natural products CN1C(=O)N(C)C(=O)C2=C1N(C)C=N2 LPHGQDQBBGAPDZ-UHFFFAOYSA-N 0.000 description 1
- 239000002147 L01XE04 - Sunitinib Substances 0.000 description 1
- 239000005511 L01XE05 - Sorafenib Substances 0.000 description 1
- 108010007859 Lisinopril Proteins 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- ZDZOTLJHXYCWBA-VCVYQWHSSA-N N-debenzoyl-N-(tert-butoxycarbonyl)-10-deacetyltaxol Chemical compound O([C@H]1[C@H]2[C@@](C([C@H](O)C3=C(C)[C@@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)C=4C=CC=CC=4)C[C@]1(O)C3(C)C)=O)(C)[C@@H](O)C[C@H]1OC[C@]12OC(=O)C)C(=O)C1=CC=CC=C1 ZDZOTLJHXYCWBA-VCVYQWHSSA-N 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- ZCQWOFVYLHDMMC-UHFFFAOYSA-N Oxazole Chemical compound C1=COC=N1 ZCQWOFVYLHDMMC-UHFFFAOYSA-N 0.000 description 1
- 229930012538 Paclitaxel Natural products 0.000 description 1
- PCNDJXKNXGMECE-UHFFFAOYSA-N Phenazine Natural products C1=CC=CC2=NC3=CC=CC=C3N=C21 PCNDJXKNXGMECE-UHFFFAOYSA-N 0.000 description 1
- WTKZEGDFNFYCGP-UHFFFAOYSA-N Pyrazole Chemical compound C=1C=NNC=1 WTKZEGDFNFYCGP-UHFFFAOYSA-N 0.000 description 1
- QNVSXXGDAPORNA-UHFFFAOYSA-N Resveratrol Natural products OC1=CC=CC(C=CC=2C=C(O)C(O)=CC=2)=C1 QNVSXXGDAPORNA-UHFFFAOYSA-N 0.000 description 1
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
- 235000021355 Stearic acid Nutrition 0.000 description 1
- RKSMVPNZHBRNNS-UHFFFAOYSA-N Succinobucol Chemical compound CC(C)(C)C1=C(O)C(C(C)(C)C)=CC(SC(C)(C)SC=2C=C(C(OC(=O)CCC(O)=O)=C(C=2)C(C)(C)C)C(C)(C)C)=C1 RKSMVPNZHBRNNS-UHFFFAOYSA-N 0.000 description 1
- 229940123237 Taxane Drugs 0.000 description 1
- 206010070863 Toxicity to various agents Diseases 0.000 description 1
- LUKBXSAWLPMMSZ-OWOJBTEDSA-N Trans-resveratrol Chemical compound C1=CC(O)=CC=C1\C=C\C1=CC(O)=CC(O)=C1 LUKBXSAWLPMMSZ-OWOJBTEDSA-N 0.000 description 1
- LEHOTFFKMJEONL-UHFFFAOYSA-N Uric Acid Chemical compound N1C(=O)NC(=O)C2=C1NC(=O)N2 LEHOTFFKMJEONL-UHFFFAOYSA-N 0.000 description 1
- TVWHNULVHGKJHS-UHFFFAOYSA-N Uric acid Natural products N1C(=O)NC(=O)C2NC(=O)NC21 TVWHNULVHGKJHS-UHFFFAOYSA-N 0.000 description 1
- 208000036142 Viral infection Diseases 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 239000008186 active pharmaceutical agent Substances 0.000 description 1
- 229960000643 adenine Drugs 0.000 description 1
- 229940009456 adriamycin Drugs 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 229960004601 aliskiren Drugs 0.000 description 1
- 125000003545 alkoxy group Chemical group 0.000 description 1
- HSFWRNGVRCDJHI-UHFFFAOYSA-N alpha-acetylene Natural products C#C HSFWRNGVRCDJHI-UHFFFAOYSA-N 0.000 description 1
- 150000001412 amines Chemical class 0.000 description 1
- 125000003277 amino group Chemical group 0.000 description 1
- 238000004873 anchoring Methods 0.000 description 1
- 239000002246 antineoplastic agent Substances 0.000 description 1
- 125000003118 aryl group Chemical group 0.000 description 1
- 125000004429 atom Chemical group 0.000 description 1
- 125000000852 azido group Chemical group *N=[N+]=[N-] 0.000 description 1
- 230000008827 biological function Effects 0.000 description 1
- 239000012620 biological material Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 229960001573 cabazitaxel Drugs 0.000 description 1
- BMQGVNUXMIRLCK-OAGWZNDDSA-N cabazitaxel Chemical compound O([C@H]1[C@@H]2[C@]3(OC(C)=O)CO[C@@H]3C[C@@H]([C@]2(C(=O)[C@H](OC)C2=C(C)[C@@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)C=3C=CC=CC=3)C[C@]1(O)C2(C)C)C)OC)C(=O)C1=CC=CC=C1 BMQGVNUXMIRLCK-OAGWZNDDSA-N 0.000 description 1
- 229960001948 caffeine Drugs 0.000 description 1
- VJEONQKOZGKCAK-UHFFFAOYSA-N caffeine Natural products CN1C(=O)N(C)C(=O)C2=C1C=CN2C VJEONQKOZGKCAK-UHFFFAOYSA-N 0.000 description 1
- 125000002837 carbocyclic group Chemical group 0.000 description 1
- 239000011545 carbonate/bicarbonate buffer Substances 0.000 description 1
- 125000006297 carbonyl amino group Chemical group [H]N([*:2])C([*:1])=O 0.000 description 1
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 description 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
- 150000007942 carboxylates Chemical class 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 229960001231 choline Drugs 0.000 description 1
- VZWXIQHBIQLMPN-UHFFFAOYSA-N chromane Chemical compound C1=CC=C2CCCOC2=C1 VZWXIQHBIQLMPN-UHFFFAOYSA-N 0.000 description 1
- WCZVZNOTHYJIEI-UHFFFAOYSA-N cinnoline Chemical group N1=NC=CC2=CC=CC=C21 WCZVZNOTHYJIEI-UHFFFAOYSA-N 0.000 description 1
- 229960004316 cisplatin Drugs 0.000 description 1
- 239000000084 colloidal system Substances 0.000 description 1
- 238000004440 column chromatography Methods 0.000 description 1
- 229910052802 copper Inorganic materials 0.000 description 1
- 125000004093 cyano group Chemical group *C#N 0.000 description 1
- 125000000753 cycloalkyl group Chemical group 0.000 description 1
- 229940104302 cytosine Drugs 0.000 description 1
- 229950004456 darapladib Drugs 0.000 description 1
- STQGQHZAVUOBTE-VGBVRHCVSA-N daunorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(C)=O)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 STQGQHZAVUOBTE-VGBVRHCVSA-N 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 238000012631 diagnostic technique Methods 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- ZPTBLXKRQACLCR-XVFCMESISA-N dihydrouridine Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)CC1 ZPTBLXKRQACLCR-XVFCMESISA-N 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 230000005750 disease progression Effects 0.000 description 1
- 229960003668 docetaxel Drugs 0.000 description 1
- 238000002592 echocardiography Methods 0.000 description 1
- 229960001123 epoprostenol Drugs 0.000 description 1
- 125000002534 ethynyl group Chemical group [H]C#C* 0.000 description 1
- 230000008020 evaporation Effects 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 229960002949 fluorouracil Drugs 0.000 description 1
- 235000019253 formic acid Nutrition 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- NGGMYCMLYOUNGM-CSDLUJIJSA-N fumagillin Chemical compound C([C@H]([C@H]([C@@H]1[C@]2(C)[C@H](O2)CC=C(C)C)OC)OC(=O)\C=C\C=C\C=C\C=C\C(O)=O)C[C@@]21CO2 NGGMYCMLYOUNGM-CSDLUJIJSA-N 0.000 description 1
- QTQAWLPCGQOSGP-GBTDJJJQSA-N geldanamycin Chemical class N1C(=O)\C(C)=C/C=C\[C@@H](OC)[C@H](OC(N)=O)\C(C)=C/[C@@H](C)[C@@H](O)[C@H](OC)C[C@@H](C)CC2=C(OC)C(=O)C=C1C2=O QTQAWLPCGQOSGP-GBTDJJJQSA-N 0.000 description 1
- 229960005277 gemcitabine Drugs 0.000 description 1
- 229940080856 gleevec Drugs 0.000 description 1
- RWSXRVCMGQZWBV-WDSKDSINSA-N glutathione Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O RWSXRVCMGQZWBV-WDSKDSINSA-N 0.000 description 1
- 235000003969 glutathione Nutrition 0.000 description 1
- 229960003180 glutathione Drugs 0.000 description 1
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 1
- 229910052736 halogen Inorganic materials 0.000 description 1
- 150000002367 halogens Chemical class 0.000 description 1
- 125000000623 heterocyclic group Chemical group 0.000 description 1
- 229960001330 hydroxycarbamide Drugs 0.000 description 1
- 229960002411 imatinib Drugs 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- PZOUSPYUWWUPPK-UHFFFAOYSA-N indole Natural products CC1=CC=CC2=C1C=CN2 PZOUSPYUWWUPPK-UHFFFAOYSA-N 0.000 description 1
- RKJUIXBNRJVNHR-UHFFFAOYSA-N indolenine Natural products C1=CC=C2CC=NC2=C1 RKJUIXBNRJVNHR-UHFFFAOYSA-N 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- YCPOHTHPUREGFM-UHFFFAOYSA-N irbesartan Chemical compound O=C1N(CC=2C=CC(=CC=2)C=2C(=CC=CC=2)C=2[N]N=NN=2)C(CCCC)=NC21CCCC2 YCPOHTHPUREGFM-UHFFFAOYSA-N 0.000 description 1
- 229960002198 irbesartan Drugs 0.000 description 1
- 229910052742 iron Inorganic materials 0.000 description 1
- JEIPFZHSYJVQDO-UHFFFAOYSA-N iron(III) oxide Inorganic materials O=[Fe]O[Fe]=O JEIPFZHSYJVQDO-UHFFFAOYSA-N 0.000 description 1
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- CTAPFRYPJLPFDF-UHFFFAOYSA-N isoxazole Chemical compound C=1C=NOC=1 CTAPFRYPJLPFDF-UHFFFAOYSA-N 0.000 description 1
- 238000002372 labelling Methods 0.000 description 1
- 239000003446 ligand Substances 0.000 description 1
- 238000012417 linear regression Methods 0.000 description 1
- RLAWWYSOJDYHDC-BZSNNMDCSA-N lisinopril Chemical compound C([C@H](N[C@@H](CCCCN)C(=O)N1[C@@H](CCC1)C(O)=O)C(O)=O)CC1=CC=CC=C1 RLAWWYSOJDYHDC-BZSNNMDCSA-N 0.000 description 1
- 229960002394 lisinopril Drugs 0.000 description 1
- KJJZZJSZUJXYEA-UHFFFAOYSA-N losartan Chemical compound CCCCC1=NC(Cl)=C(CO)N1CC1=CC=C(C=2C(=CC=CC=2)C=2[N]N=NN=2)C=C1 KJJZZJSZUJXYEA-UHFFFAOYSA-N 0.000 description 1
- 229960004773 losartan Drugs 0.000 description 1
- 238000004949 mass spectrometry Methods 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- SGDBTWWWUNNDEQ-LBPRGKRZSA-N melphalan Chemical compound OC(=O)[C@@H](N)CC1=CC=C(N(CCCl)CCCl)C=C1 SGDBTWWWUNNDEQ-LBPRGKRZSA-N 0.000 description 1
- 229960001924 melphalan Drugs 0.000 description 1
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 description 1
- XELZGAJCZANUQH-UHFFFAOYSA-N methyl 1-acetylthieno[3,2-c]pyrazole-5-carboxylate Chemical compound CC(=O)N1N=CC2=C1C=C(C(=O)OC)S2 XELZGAJCZANUQH-UHFFFAOYSA-N 0.000 description 1
- WDPFJWLDPVQCAJ-UHFFFAOYSA-N n-[2-(diethylamino)ethyl]-2-[2-[(4-fluorophenyl)methylsulfanyl]-4-oxo-6,7-dihydro-5h-cyclopenta[d]pyrimidin-1-yl]-n-[[4-[4-(trifluoromethyl)phenyl]phenyl]methyl]acetamide Chemical compound C1=2CCCC=2C(=O)N=C(SCC=2C=CC(F)=CC=2)N1CC(=O)N(CCN(CC)CC)CC(C=C1)=CC=C1C1=CC=C(C(F)(F)F)C=C1 WDPFJWLDPVQCAJ-UHFFFAOYSA-N 0.000 description 1
- 125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 230000000269 nucleophilic effect Effects 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
- 238000011275 oncology therapy Methods 0.000 description 1
- WCPAKWJPBJAGKN-UHFFFAOYSA-N oxadiazole Chemical compound C1=CON=N1 WCPAKWJPBJAGKN-UHFFFAOYSA-N 0.000 description 1
- 229960001592 paclitaxel Drugs 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 125000005010 perfluoroalkyl group Chemical group 0.000 description 1
- 229960001006 picotamide Drugs 0.000 description 1
- 239000013641 positive control Substances 0.000 description 1
- CPTBDICYNRMXFX-UHFFFAOYSA-N procarbazine Chemical compound CNNCC1=CC=C(C(=O)NC(C)C)C=C1 CPTBDICYNRMXFX-UHFFFAOYSA-N 0.000 description 1
- 229960000624 procarbazine Drugs 0.000 description 1
- BDERNNFJNOPAEC-UHFFFAOYSA-N propan-1-ol Chemical compound CCCO BDERNNFJNOPAEC-UHFFFAOYSA-N 0.000 description 1
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 125000002568 propynyl group Chemical group [*]C#CC([H])([H])[H] 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- PBMFSQRYOILNGV-UHFFFAOYSA-N pyridazine Chemical compound C1=CC=NN=C1 PBMFSQRYOILNGV-UHFFFAOYSA-N 0.000 description 1
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 1
- 229960005038 quinisocaine Drugs 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 235000021283 resveratrol Nutrition 0.000 description 1
- 229940016667 resveratrol Drugs 0.000 description 1
- 229930195734 saturated hydrocarbon Natural products 0.000 description 1
- 239000004054 semiconductor nanocrystal Substances 0.000 description 1
- 239000000741 silica gel Substances 0.000 description 1
- 229910002027 silica gel Inorganic materials 0.000 description 1
- 229910052710 silicon Inorganic materials 0.000 description 1
- 229910052709 silver Inorganic materials 0.000 description 1
- 239000001509 sodium citrate Substances 0.000 description 1
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 1
- 210000004872 soft tissue Anatomy 0.000 description 1
- 239000002047 solid lipid nanoparticle Substances 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 238000000527 sonication Methods 0.000 description 1
- 229960003787 sorafenib Drugs 0.000 description 1
- 238000011105 stabilization Methods 0.000 description 1
- 239000008117 stearic acid Substances 0.000 description 1
- 229950009108 succinobucol Drugs 0.000 description 1
- WINHZLLDWRZWRT-ATVHPVEESA-N sunitinib Chemical compound CCN(CC)CCNC(=O)C1=C(C)NC(\C=C/2C3=CC(F)=CC=C3NC\2=O)=C1C WINHZLLDWRZWRT-ATVHPVEESA-N 0.000 description 1
- 229960001796 sunitinib Drugs 0.000 description 1
- 238000006557 surface reaction Methods 0.000 description 1
- RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 description 1
- RCINICONZNJXQF-XAZOAEDWSA-N taxol® Chemical compound O([C@@H]1[C@@]2(CC(C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3(C21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-XAZOAEDWSA-N 0.000 description 1
- 229960005187 telmisartan Drugs 0.000 description 1
- 229950001286 terutroban Drugs 0.000 description 1
- 150000003536 tetrazoles Chemical class 0.000 description 1
- 229960004559 theobromine Drugs 0.000 description 1
- 230000004797 therapeutic response Effects 0.000 description 1
- 235000019149 tocopherols Nutrition 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 229930195735 unsaturated hydrocarbon Natural products 0.000 description 1
- 229940116269 uric acid Drugs 0.000 description 1
- BHLXTPHDSZUFHR-UHFFFAOYSA-N varespladib Chemical compound CCC1=C(C(=O)C(N)=O)C2=C(OCC(O)=O)C=CC=C2N1CC1=CC=CC=C1 BHLXTPHDSZUFHR-UHFFFAOYSA-N 0.000 description 1
- 229950006583 varespladib Drugs 0.000 description 1
- 239000003071 vasodilator agent Substances 0.000 description 1
- 239000013598 vector Substances 0.000 description 1
- 125000000391 vinyl group Chemical group [H]C([*])=C([H])[H] 0.000 description 1
- 229920002554 vinyl polymer Polymers 0.000 description 1
- 230000009385 viral infection Effects 0.000 description 1
- 230000003612 virological effect Effects 0.000 description 1
- 229940075420 xanthine Drugs 0.000 description 1
- 229910006297 γ-Fe2O3 Inorganic materials 0.000 description 1
- QUEDXNHFTDJVIY-UHFFFAOYSA-N γ-tocopherol Chemical class OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1 QUEDXNHFTDJVIY-UHFFFAOYSA-N 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/51—Nanocapsules; Nanoparticles
- A61K9/5107—Excipients; Inactive ingredients
- A61K9/5123—Organic compounds, e.g. fats, sugars
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
- A61K31/343—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide condensed with a carbocyclic ring, e.g. coumaran, bufuralol, befunolol, clobenfurol, amiodarone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline
- A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
- A61K31/355—Tocopherols, e.g. vitamin E
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
- A61K31/558—Eicosanoids, e.g. leukotrienes or prostaglandins having heterocyclic rings containing oxygen as the only ring hetero atom, e.g. thromboxanes
- A61K31/5585—Eicosanoids, e.g. leukotrienes or prostaglandins having heterocyclic rings containing oxygen as the only ring hetero atom, e.g. thromboxanes having five-membered rings containing oxygen as the only ring hetero atom, e.g. prostacyclin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
- A61K49/18—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes
- A61K49/1806—Suspensions, emulsions, colloids, dispersions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
- A61K49/18—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes
- A61K49/1818—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles
- A61K49/1821—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles coated or functionalised microparticles or nanoparticles
- A61K49/1824—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles coated or functionalised microparticles or nanoparticles coated or functionalised nanoparticles
- A61K49/1827—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles coated or functionalised microparticles or nanoparticles coated or functionalised nanoparticles having a (super)(para)magnetic core, being a solid MRI-active material, e.g. magnetite, or composed of a plurality of MRI-active, organic agents, e.g. Gd-chelates, or nuclei, e.g. Eu3+, encapsulated or entrapped in the core of the coated or functionalised nanoparticle
- A61K49/1833—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles coated or functionalised microparticles or nanoparticles coated or functionalised nanoparticles having a (super)(para)magnetic core, being a solid MRI-active material, e.g. magnetite, or composed of a plurality of MRI-active, organic agents, e.g. Gd-chelates, or nuclei, e.g. Eu3+, encapsulated or entrapped in the core of the coated or functionalised nanoparticle having a (super)(para)magnetic core coated or functionalised with a small organic molecule
- A61K49/1839—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles coated or functionalised microparticles or nanoparticles coated or functionalised nanoparticles having a (super)(para)magnetic core, being a solid MRI-active material, e.g. magnetite, or composed of a plurality of MRI-active, organic agents, e.g. Gd-chelates, or nuclei, e.g. Eu3+, encapsulated or entrapped in the core of the coated or functionalised nanoparticle having a (super)(para)magnetic core coated or functionalised with a small organic molecule the small organic molecule being a lipid, a fatty acid having 8 or more carbon atoms in the main chain, or a phospholipid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
- A61K49/18—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes
- A61K49/1818—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles
- A61K49/1887—Agglomerates, clusters, i.e. more than one (super)(para)magnetic microparticle or nanoparticle are aggregated or entrapped in the same maxtrix
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/127—Liposomes
- A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes, liposomes coated with polymers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5094—Microcapsules containing magnetic carrier material, e.g. ferrite for drug targeting
Definitions
- the invention relates to non-polymeric lipid-based nanocarrier compositions loaded with metal nanoparticles and at least one therapeutic agent.
- the nanoparticle technology has allowed the implementation of novel multifunctional nanoparticles for disease, detection, therapy and treatment monitoring.
- Magnetic Resonance Imaging is a worldwide-used non-invasive imaging and diagnostic technique, which is very efficient for imaging soft tissues and provides detailed anatomical images of the body.
- Ultrasmall superparamagnetic iron oxide nanoparticles are currently used as contrast agent in magnetic resonance imaging.
- the theranostic approach refers to molecular/macromolecular targeting vectors and nano-platform technologies that incorporate both diagnostic and therapeutic functionalities. These entities can be used for simultaneous targeted drug delivery and release, as well as diagnosis, which includes monitoring disease progression and response to therapy.
- this approach can be used for selecting a safe and efficient dose of therapeutic agent, recognizing adverse effects at an early stage of therapy and real-time monitoring of therapy, making it possible to adapt the treatment to the individual patients as a function of the inter-individual variability in their therapeutic responses.
- Quantum dot lipid oligonucleotide bioconjugates are studied in A. Aimé et al., Bioconjugate Chem., 2013, 24, 1345-1355. These bioconjugates consist of fluorescent semiconductor nanocrystals, named quantum dots, encapsulated by nucleolipids and lipid oligonucleotide conjugates, with a view to providing functionalized quantum dots with recognition and detection properties.
- lipid-based theranostic systems loaded with nanoparticles and a therapeutic agent which are non-polymeric systems, could be used, in particular, for drug targeting, drug delivery and treatment monitoring, while avoiding the side-effects usually related to the use of toxic active ingredients, in particular in cancer therapy.
- nucleoside-lipids also called nucleolipids
- the metal nanoparticles are associated to each other as clusters by hydrophilic/hydrophobic interactions with the nucleolipids, while such clusters are not formed when using lipids instead of nucleolipids.
- Said nucleolipids also serve to entrap the therapeutic agent(s), through hydrophilic/hydrophobic interactions and are present at the interface with the outer aqueous medium.
- the lipid-based nanocarrier composition according to the invention allows a high content in active principle and the formation of nanoparticles which can be used for imaging purpose.
- nanoparticles are solid lipid nanoparticles loaded with metal nanoparticles and a therapeutic agent, and stabilized by the nucleolipids.
- lipid such as, for example 1,2-Dioleyl-sn-Glycero-3-phosphocholine (DOPC) in association with metal nanoparticles
- DOPC 1,2-Dioleyl-sn-Glycero-3-phosphocholine
- the magnetic sensitivity of the lipid-based nanocarrier composition is enhanced through these stable supramolecular constructs, thereby also increasing the magnetic resonance signal, and thus the detection of the lipid-based nanocarrier composition of the invention, which plays a decisive role in theranostic approaches.
- the invention thus relates to a lipid-based nanocarrier composition
- a lipid-based nanocarrier composition comprising
- nanocarrier is meant that the theranostic system of the invention has an overall size (average diameter) of approximately 20 to 300 nm.
- X preferably represents an oxygen atom.
- straight or branched C 1 -C 6 alkyl is understood, for example, a methyl, ethyl, propyl, i-propyl, n-butyl, i-butyl, test-butyl, preferably methyl or ethyl.
- Preferred C 2 -C 30 hydrocarbon chains are C 8 -C 30 , preferably C 8 -C 26 , more preferably C 16 -C 20 hydrocarbon chains.
- Preferred linear or branched C 2 -C 30 alkyl chains are C 8 -C 30 , preferably C 8 -C 26 , more preferably C 16 -C 20 linear or branched alkyl chains.
- Preferred C 2 -C 30 acyl chains are C 8 -C 30 , preferably C 8 -C 26 , more preferably C 16 -C 20 acyl chains.
- the alkyl, acyl or hydrocarbon chain is preferably a C 8 -C 30 alkyl, acyl or hydrocarbon chain.
- L 1 and L 2 are not simultaneously hydrogen.
- the invention relates, in particular, to a lipid-based nanocarrier composition
- a lipid-based nanocarrier composition comprising
- the purine or pyrimidine base can be, for example, selected from, adenine, guanine, cytosine, xanthine, hypoxanthine, uric acid, caffeine, theobromine, uracile, thymine, dihydrouridine, and their derivatives.
- Thymine and uracile are preferred.
- the purine or pyrimidine base can be substituted by at least one substituent selected from, for example, a halogen, an amino group, a carboxy group, a carbonyl group, a carbonylamino group, a hydroxy, azido, cyano, thiol, a C 1 -C 6 straight or branched alkyl, cycloalkyl, perfluoroalkyl, alkyloxy (for example, methoxy), oxycarbonyl, vinyl, ethynyl, propynyl, acyl group etc.
- substituent selected from, for example, a halogen, an amino group, a carboxy group, a carbonyl group, a carbonylamino group, a hydroxy, azido, cyano, thiol, a C 1 -C 6 straight or branched alkyl, cycloalkyl, perfluoroalkyl, alkyloxy (for example, methoxy), oxycarbon
- derivatives of a purine or pyrimidine base is meant, for example, a non-natural mono- or bi-cyclic heterocyclic base in which each cycle has 4 to 7 members, optionally substituted as stated above for the purine or pyrimidine base.
- non-natural heterocyclic base is meant a universal base, such as, for example, 3-nitropyrrole, 4-nitroimidazole or 5-nitroindole, which do not exist in nature.
- heteroaryl comprising 1 to 4 nitrogen atoms is meant a mono- or bi-cyclic carbocyclic group, aromatic or partially unsaturated, comprising 5 to 12 atoms in total, interrupted by 1 to 4 nitrogen atoms, which can be, for example, selected from furane, pyrrole, oxazole, oxadiazole, isoxazole, pyrazole, triazole, tetrazole, imidazole, pyridine, pyrimidine, pyridazine, pyrazine, benzofurane, indole, quinoleine, isoquinoleine, chromane, naphtyridine and benzodiazine groups, triazole being preferred.
- X is an oxygen atom
- B is thymine or uracile
- L 1 and L 2 are oxycarbonyl —O—C(O)— groups which are substituted by a linear or branched C 2 -C 30 , preferably C 8 -C 30 , hydrocarbon chain, preferably C 8 -C 26 , more preferably C 16 -C 20 , saturated or partially unsaturated; or
- L 1 is a phosphate group which is substituted by diacylglycerol in which each acyl group is C 2 -C 30 , preferably C 8 -C 30 , more preferably C 8 -C 26 , even more preferably C 16 -C 20 , and L 2 is hydrogen;
- R 3 is hydroxy, a NR 4 R 5 R 6 group in which R 4 , R 5 and R 6 represent a hydrogen atom or a —O—C(O)—(CH 2 ) q —C(O)—O[(CH 2 ) 2 —O] r —H group in which q is an integer from 2 to 6 and r is an integer from 4 to 30, preferably from 10 to 20.
- DOTAU N-[5′-(2′,3′-dioleoyl)uridine]-N′,N′,N′-trimethylammonium (DOTAU) (CAS Registry Number: 868226-06-6),
- the lipid-based nanocarrier composition according to the invention comprises at least 2 different compounds of formula (I).
- the lipid-based nanocarrier composition can comprise at least one co-lipid in addition to the compound(s) of formula (I),
- co-lipid a compound used in combination with the compound of formula (I), which contributes to the production of the structure of the lipid-based nanocarrier composition.
- a zwitterionic co-lipid will be used.
- Said co-lipid can be, for example, chosen from dioleylphosphatidylcholine (DOPC), dioleylphosphatidyluridinephosphatidyl-choline (DOUPC) or dioleylphosphatidyleinanolamine (DOPE).
- DOPC dioleylphosphatidylcholine
- DOUPC dioleylphosphatidyluridinephosphatidyl-choline
- DOPE dioleylphosphatidyleinanolamine
- These compounds can play the role of co-lipid when they are used in a mixture with a compound of formula (I).
- DOUPC dioleylphosphatidyluridinephosphatidylcholine
- they will either play the role of a compound of formula (I) or, in combination with another compound of formula (I), the role of co-lipid.
- the lipid-based nanocarrier composition according to the invention contains a plurality of metal nanoparticles, in particular 10 to 90% (w/w) of metal nanoparticles, preferably 50 to 80%.
- the metal nanoparticles contain, preferably, metal oxides which can be, for example, selected from iron oxide (magnetite Fe 3 O 4 , maghemite ⁇ -Fe 2 O 3 , or other Co ferrite or Ni ferrite) which is known for its magnetic properties while metals (Au, Ag, Cu, Si, Ge, Fe, Co etc), metal alloys (FeCo, FePt, CoPt, FeBi etc.) and metal chalcogenides (CdS, CdSe, CdSe, ZnS . . . etc.) can be used for their plasmonic, luminescent or magnetic properties which are interesting in the aim to the development of a contrast agent or a labelling tool for bioimaging, tacking or sensoring.
- metal oxides which can be, for example, selected from iron oxide (magnetite Fe 3 O 4 , maghemite ⁇ -Fe 2 O 3 , or other Co ferrite or Ni ferrite) which is known for its magnetic properties while metals
- the metal nanoparticles have an overall size (average diameter) of approximately from 2 nm to 20 nm, preferably 5 to 10 nm.
- the metal nanoparticles contained in the lipid-based nanocarrier compositions according to the invention may be mono-disperse (for example, they consist of a population having an average diameter centered around 10 nm), or mono- and/or poly-disperse (such as, for example, two populations having an average diameter centered around 4 nm and 10 nm), or else poly-disperse (different populations having different average diameters ranging from 2 nm and 20 nm).
- Iron oxide nanoparticles are preferred.
- the metal nanoparticles contained in the lipid-based nanocarrier compositions according to the invention can be, for instance, surface functionalized nanoparticles, or any type of nanoparticle presenting surface reactive groups, with a size comprised between 2 nm arid 20 nm, preferably 5 to 10 nm, having a surface modified by grafting of amphiphilic or fatty ligand composed of an anchoring function—mainly carboxylates, phosphonate groups used for metal oxide and amine, thiol functions or other strong nucleophilic functions for metal nanoparticles such as gold nanoparticles—and a hydrophobic moiety which could be saturated or unsaturated hydrocarbon chains or perfluorinated carbon chains.
- an anchoring function mainly carboxylates, phosphonate groups used for metal oxide and amine, thiol functions or other strong nucleophilic functions for metal nanoparticles such as gold nanoparticles—and a hydrophobic moiety which could be saturated or unsaturated hydrocarbon chains or perfluor
- coprecipited hydrophobic iron oxide nanoparticles have been prepared as previously published (G. A. van Ewijk, G. J. Vroege, A. P. Philipse, Convenient preparation methods for magnetic colloids, J. Magn. Magn. Mater. 201 (1999) 31-33) using stearic acid as fatty acid.
- the metal nanoparticles have a surface functionalization which provides them with hydrophobic properties. For instance they bear fatty acid residues on their surface.
- therapeutic agent is meant, for example, a natural or synthetic molecule used for preventing or treating a pathological condition, or restoring a biological function, in vitro or in vivo, in particular in animals, in particular in human beings, or else in isolated cells.
- said therapeutic agent can be selected, for example, from anti-tumoral agents, antibiotic agents, anti-microbial agents, analgesic agents, anti-histaminic agents, bronchodilators agents, agents which are active on the central nervous system, anti-hypertension agents or agents which are active on the cardiovascular system (in particular vasodilator agents, anti-atherosclerosis agents such as agents having a platelet anti-aggregating activity), nucleic acids and their fragments; peptides, oligopeptides, proteins, antigens, antibodies or else stem cells etc.
- Anti-cancer agents are of particular interest, such as, for example, sorafenib, sunitinib, taxanes (docetaxel, paclitaxel, cabazitaxel . . . ), doxorubicine, adriamycin, daunomycin, melphalan, gemcitabine, cisplatin, derivatives of gemcitabine, or derivative of cisplatin, imatinib (Gleevec®), 5-fluorouracil, 9-aminocamptothecin, amine-modified geldanamycin, Taxol®, procarbazine or hydroxyurea.
- sorafenib sunitinib
- taxanes docetaxel, paclitaxel, cabazitaxel . . .
- doxorubicine doxorubicine
- adriamycin daunomycin
- melphalan gemcitabine
- gemcitabine c
- Anti-atherosclerosis agents such as, for example, tocopherols, resveratrol, anthocyanes, succinobucol, prostacycline, terutroban, picotamide, varespladib, darapladib, fumagilline, chemokins (CXCR3, IL10), aliskiren, lisinopril, losartan, irbesartan, telmisartan, epleronone, apolipoproteine A1 (APOA-1) or glutathion are also of particular interest.
- tocopherols such as, for example, tocopherols, resveratrol, anthocyanes, succinobucol, prostacycline, terutroban, picotamide, varespladib, darapladib, fumagilline, chemokins (CXCR3, IL10), aliskiren, lisinopril, losartan
- the invention also relates to a process for preparing a lipid-based nanocarrier composition comprising metal nanoparticles and at least one therapeutic agent, as described above, which comprises the following steps:
- Preferred reaction conditions are as follows:
- the organic solvent can be selected, for example, from ether, choloroform, methylene chloride, ethyl acetate, butanol, propanol, ethanol and methanol;
- the aqueous medium is water
- the evaporation of the organic solvent is carried out under reduced pressure, namely, for example, the pressure is reduced from 1 bar to 5 mbar;
- the lipid-based nanocarrier composition is recovered by centrifugation, for example at 14000 rpm during 15 to 30 min.
- the pellet containing the lipid-based nanocarrier composition may be re-suspended in water.
- the therapeutic agent when contained in the lipid-based nanocarrier compositions according to the invention as defined above, will be present at a concentration of about of 0.1 ng/mL to 10 mg/mL, and metal nanoparticles at a concentration of about of 0.1 ng/mL to 10 mg/mL, in the aqueous phase.
- the invention also relates to the use of a lipid-based nanocarrier composition as an agent for transportation, vectorization, cellular delivery cellular targeting or cellular localization of at least one therapeutic agent, in particular for imaging guided therapy.
- the lipid-based nanocarrier composition according to the invention may be used in various therapeutic fields relating to diseases and/or disorders such as cancers, atherosclerosis, viral and non-viral infections, immunity disorders, inflammation etc.
- the invention also concerns pharmaceutical compositions containing a lipid-based nanocarrier composition as described above and a pharmaceutically acceptable carrier.
- DOPC 1,2-Dioleyl-sn-Glycero-3-phosphocholine
- Thymidine 3′-(1,2-dipalmitoyl-sn-glycero-3-phosphate) also called diC16dT
- CAS Registry Number: 1160002-70-9 and
- FIG. 1 shows the size distribution by intensity measured by Dynamic Light Scattering (DLS) ( FIG. 1A ) and the zeta potential distribution ( FIG. 1B ) of DOTAU nanoparticles (control).
- DLS Dynamic Light Scattering
- FIG. 2 shows the size distribution by intensity measured by Dynamic Light Scattering (DLS) ( FIG. 2A ) and the Zeta potential distribution ( FIG. 2B ) of nanoparticles of diC16dT (control).
- DLS Dynamic Light Scattering
- FIG. 3 shows the size distribution by intensity measured by Dynamic Light Scattering (DLS) ( FIG. 3A ) and the Zeta potential distribution ( FIG. 3B ) of a lipid-based (DOTAU) nanocarrier composition containing ⁇ -tocopherol.
- DLS Dynamic Light Scattering
- DOTAU lipid-based nanocarrier composition containing ⁇ -tocopherol.
- FIG. 4 shows the size distribution by intensity measured by Dynamic Light Scattering (DLS) ( FIG. 4A ) and the Zeta potential distribution ( FIG. 4B ) of a lipid-based (diC16dT, DOPC (co-lipid) and DOU-PEG2000) nanocarrier composition containing prostacycline (PGl2.Na).
- DLS Dynamic Light Scattering
- FIG. 4B Zeta potential distribution of a lipid-based (diC16dT, DOPC (co-lipid) and DOU-PEG2000) nanocarrier composition containing prostacycline (PGl2.Na).
- FIG. 5 shows a SDS Page gel experiment of a lipid-based (DOTAU) nanocarrier composition containing Apolipoprotein-A1 (APOA1).
- DOTAU lipid-based nanocarrier composition containing Apolipoprotein-A1
- FIG. 6 shows the size distribution by intensity measured by Dynamic Light Scattering (DLS) ( FIG. 6A ) and the Zeta potential distribution ( FIG. 6B ) of a lipid-based (DOTAU) nanocarrier composition containing Apolipoprotein-A1 (APOA1).
- DLS Dynamic Light Scattering
- APOA Apolipoprotein-A1
- FIG. 7 shows the particule size of iron oxide nanoparticles clusters encapsulated by DOTAU or diC16dT (preparations 1 and 2) or of a DOTAU-based nanocarrier composition comprising iron oxide nanoparticles and ⁇ -tocopherol (example 1) determined with a Zetasizer 3000 HAS MALVERN.
- FIG. 8 shows the detection standard curve for DOTAU ( FIG. 8A ) and ⁇ -tocopherol ( FIG. 8B ).
- FIG. 9 shows the HPLC analysis of iron oxide nanoparticles clusters encapsulated by DOTAU prepared in preparation 1 and of a DOTAU-based nanocarrier composition comprising iron oxide nanoparticles and ⁇ -tocopherol prepared in example 1.
- FIG. 10 shows a stability comparison of iron oxide nanoparticles clusters encapsulated by a lipid (DOPC) or by a nucleolipid (DOTAU).
- DOPC lipid
- DOTAU nucleolipid
- FIG. 11 shows the Magnetic Resonance Relaxometry study of preparations of cationic or anionic metal nanoparticles.
- FIG. 12 shows the platelet anti-aggregating activity of the nanocarrier composition of example 2.
- PREPARATION 1 ENCAPSULATION OF IRON OXIDE NANOPARTICLES CLUSTERS BY DOTAU (CONTROL)
- DOTAU positively charged nucleolipid
- iron oxide nanoparticles 10 mg/mL in ether
- DLS Dynamic Light Scattering
- DIC16dT was prepared as disclosed in WO2010/13676.
- DOU-PEG2000 was prepared according to K. Oumzil et al., 2011, J. Control. Release, doi:10.1016/j. j conrel.2011.02.008.
- the organic phase was added dropwise into the aqueous phase (2 ml of Milli-Q Water) placed in glass tube under stirring by vortex. Then the mixture was placed in glass flask.
- DLS Dynamic Light Scattering
- DOTAU positively charged nucleolipid
- ⁇ -tocopherol Sigma Aldrich, 50 mg/mL in ether
- iron oxide nanoparticles 10 mg/mL in ether
- DLS Dynamic Light Scattering
- DLS Dynamic Light Scattering
- DLS Dynamic Light Scattering
- a reverse phase U-HPLC method was developed for nucleolipid (DOTAU) and ⁇ -tocopherol quantification from the lipid-based nanocarrier composition containing iron oxide nanoparticles. This method allows the separation of the DOTAU and lipid-based (DOTAU) nanocarrier composition within 5 min.
- the separation was carried out with a column Syncronis C18 50 ⁇ 2.1 mm, 1.7 ⁇ m with a mobile phase composed of MeOH+0.1% HCOOH.
- the flow rate was set to 0.2 mL/min.
- the detection was performed at 293 nm and 260 nm for ⁇ -tocopherol and DOTAU, respectively.
- the injected volume was 1.0 ⁇ L, which allows the detection of DOTAU and ⁇ -tocopherol at thresholds of 5 ng and 15 ng, respectively.
- Standard curves for DOTAU and ⁇ -tocopherol were generated by determining the intensity of signal versus concentrations.
- FIGS. 9A and 9 B The HPLC analysis is shown on FIGS. 9A (260 nm) and 9 B (293 nm).
- This method has the advantage of using a low amount for analysis and a short analysis time, and has compatibility with mass spectrometry, which can be useful for biological analysis.
- nucleolipids of formula (I) In order to show the role of nucleolipids of formula (I) in the stabilisation of encapsulated metal nanoparticles, a control experiment was achieved with DiOleylPhosphatidylCholine (DOPC) only, in the absence of nucleolipid.
- DOPC DiOleylPhosphatidylCholine
- FIG. 10 show that the nucleolipid DOTAU allows the formation of a stable collo ⁇ dal suspension (photograph A), whereas in similar conditions with the lipid DOPC a precipitate is formed, which evidences that DOPC does not provide this colloidal stabilization (photograph B).
- the mean relaxation rates, Rn, of each dilution were calculated from regions of interest (ROIs) encompassing each tube and plotted versus their corresponding Fe concentrations.
- the iron oxide nanoparticles clusters encapsulated by either cationic or anionic nucleolipids of formula (I) (preparations 1 and 2), which are part of the lipid based-nanocarrier composition of the invention, allow an improved MRI detection, due to an increased sensitivity for the imaging system.
- Platelet rich plasma was prepared by centrifugation at 20° C. for 10-15 min at 150-200 g and stored at room temperature.
- PPP Platelet-poor plasma
- PRP thrombin receptor-activating peptide -6
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Nanotechnology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Radiology & Medical Imaging (AREA)
- Dispersion Chemistry (AREA)
- Zoology (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Marine Sciences & Fisheries (AREA)
- Optics & Photonics (AREA)
- Biomedical Technology (AREA)
- Physics & Mathematics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Vascular Medicine (AREA)
- Urology & Nephrology (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Abstract
Description
- The invention relates to non-polymeric lipid-based nanocarrier compositions loaded with metal nanoparticles and at least one therapeutic agent.
- The nanoparticle technology has allowed the implementation of novel multifunctional nanoparticles for disease, detection, therapy and treatment monitoring.
- Their numerous advantages include minimizing the amount of drug needed, increasing the bioavailability, in particular for hydrophobic drugs, and reducing the drug toxicity.
- Magnetic Resonance Imaging (MRI) is a worldwide-used non-invasive imaging and diagnostic technique, which is very efficient for imaging soft tissues and provides detailed anatomical images of the body. Ultrasmall superparamagnetic iron oxide nanoparticles are currently used as contrast agent in magnetic resonance imaging.
- The theranostic approach refers to molecular/macromolecular targeting vectors and nano-platform technologies that incorporate both diagnostic and therapeutic functionalities. These entities can be used for simultaneous targeted drug delivery and release, as well as diagnosis, which includes monitoring disease progression and response to therapy.
- In addition, this approach can be used for selecting a safe and efficient dose of therapeutic agent, recognizing adverse effects at an early stage of therapy and real-time monitoring of therapy, making it possible to adapt the treatment to the individual patients as a function of the inter-individual variability in their therapeutic responses.
- Quantum dot lipid oligonucleotide bioconjugates are studied in A. Aimé et al., Bioconjugate Chem., 2013, 24, 1345-1355. These bioconjugates consist of fluorescent semiconductor nanocrystals, named quantum dots, encapsulated by nucleolipids and lipid oligonucleotide conjugates, with a view to providing functionalized quantum dots with recognition and detection properties.
- It has now been found that lipid-based theranostic systems loaded with nanoparticles and a therapeutic agent, which are non-polymeric systems, could be used, in particular, for drug targeting, drug delivery and treatment monitoring, while avoiding the side-effects usually related to the use of toxic active ingredients, in particular in cancer therapy.
- Advantageously, the use of nucleoside-lipids (also called nucleolipids) in these systems allows the formation of stable supramolecular constructs.
- Without wishing to be bound by theory, it can be hypothesized that the metal nanoparticles are associated to each other as clusters by hydrophilic/hydrophobic interactions with the nucleolipids, while such clusters are not formed when using lipids instead of nucleolipids. Said nucleolipids also serve to entrap the therapeutic agent(s), through hydrophilic/hydrophobic interactions and are present at the interface with the outer aqueous medium.
- Advantageously, it has also been found that the lipid-based nanocarrier composition according to the invention allows a high content in active principle and the formation of nanoparticles which can be used for imaging purpose.
- These nanoparticles are solid lipid nanoparticles loaded with metal nanoparticles and a therapeutic agent, and stabilized by the nucleolipids.
- Actually, while the use of a lipid, such as, for example 1,2-Dioleyl-sn-Glycero-3-phosphocholine (DOPC) in association with metal nanoparticles does not result in a formulation having the desired colloidal stability, the inventors have found, surprisingly, that such stability could be provided by the nucleolipids of formula (I) below.
- In addition, the formation of clusters of metal nanoparticles creates a larger hydrophobic reservoir, which makes it advantageously possible to entrap a higher amount of therapeutic agent.
- On the other hand, the magnetic sensitivity of the lipid-based nanocarrier composition is enhanced through these stable supramolecular constructs, thereby also increasing the magnetic resonance signal, and thus the detection of the lipid-based nanocarrier composition of the invention, which plays a decisive role in theranostic approaches.
- The invention thus relates to a lipid-based nanocarrier composition comprising
-
- a) at least one compound of formula (I)
-
- in which
- X is an oxygen atom, a sulfur atom or a methylene group,
- B is a purine or pyrimidine base, or else a non-natural mono- or bi-cyclic heterocyclic base, each ring of which comprises 4 to 7 members, optionally substituted;
- L1 and L2, identical or different, represent hydrogen, an oxycarbonyl —O—C(O)— group, a thiocarbamate —O—C(S)—NH— group, a carbonate —O—C(O)—O— group, a carbamate —O—C(O)—NH— group, an oxygen atom, a phosphate group, a phosphonate group or a heteroaryl group comprising 1 to 4 nitrogen atoms, unsubstituted or substituted by a linear or branched, saturated or unsaturated C2-C30 hydrocarbon chain,
- or also, L1 and L2, together, form a ketal group of formula
- or also L1 or L2 represents hydrogen, and the other represents a hydroxy group or a heteroaryl group comprising 1 to 4 nitrogen atoms, unsubstituted or substituted by a linear or branched C2-C30 alkyl chain.
- R1 and R2, identical or different, represent
- a linear or branched C2-C30 hydrocarbon chain, saturated or partially unsaturated, or
- a C2-C30 acyl chain,
- a diacyl chain in which each acyl chain is C2-C30,
- a diacylglycerol in which each acyl chain is C2-C30, or
- a sphingosine or ceramide group in which each acyl chain is C2-C30, or
- when L1 or L2 represents hydrogen, and the other represents a hydroxy group or a heteroaryl group comprising 1 to 4 nitrogen atoms, R1 and R2 do not exist;
- R3 represents
- a hydroxy, amino, phosphate, phosphonate, phosphatidylcholine, O-alkyl phosphatidylcholine, thiophosphate, phosphonium, NH2—R4, NHR4R5 or NR4R5R6 group in which R4, R5 and R6, identical or different, represent a hydrogen atom or a linear or branched C1-C6 alkyl chain or linear or branched C1-C6 hydroxyalkyl, or
- a linear or branched C2-C30 alkyl chain, optionally substituted by a hydroxy group, or
- a heteroaryl group containing 1 to 4 nitrogen atoms, unsubstituted or substituted by a C2-C30 alkyl, optionally substituted by a hydroxy group; or by a (CH2)m—O—(CH2)p—R9 group in which m=1 to 6 and p=0 to 20 and R9 represents hydrogen or a cyclic ketal group containing 5 to 7 carbon atoms, unsubstituted or substituted by at least one linear or branched C2-C30 alkyl, or by a sterol radical,
- or
- a —O—C(O)—(CH2)q—C(O)—O[(CH2)2—O]r—H group in which q is an integer from 2 to 6 and r is an integer from 4 to 30, preferably from 10 to 20, or also
- R3 is bound by a covalent bond to another substituent R3, identical or different, of another compound of formula (I), identical or different, in order to form a compound of formula (I) in the form of a dimer,
- b) at least one metal nanoparticle, and
- c) at least one therapeutic agent.
- By “nanocarrier” is meant that the theranostic system of the invention has an overall size (average diameter) of approximately 20 to 300 nm.
- X preferably represents an oxygen atom.
- By «straight or branched C1-C6 alkyl» is understood, for example, a methyl, ethyl, propyl, i-propyl, n-butyl, i-butyl, test-butyl, preferably methyl or ethyl.
- Preferred C2-C30 hydrocarbon chains are C8-C30, preferably C8-C26, more preferably C16-C20 hydrocarbon chains.
- Preferred linear or branched C2-C30 alkyl chains are C8-C30, preferably C8-C26, more preferably C16-C20 linear or branched alkyl chains.
- Preferred C2-C30 acyl chains are C8-C30, preferably C8-C26, more preferably C16-C20 acyl chains.
- In the definitions of L1, L2, R1 or R2, the alkyl, acyl or hydrocarbon chain is preferably a C8-C30 alkyl, acyl or hydrocarbon chain.
- Preferably, L1 and L2 are not simultaneously hydrogen.
- The invention relates, in particular, to a lipid-based nanocarrier composition comprising
-
- a) at least one compound of formula (I)
-
- in which
- X is an oxygen atom, a sulfur atom or a methylene group,
- B is a purine or pyrimidine base, or else a non-natural mono- or bi-cyclic heterocyclic base, each ring of which comprises 4 to 7 members, optionally substituted;
- L1 and L2, identical or different, represent hydrogen, an oxycarbonyl —O—C(O)— group, a thiocarbamate —O—C(S)—NH— group, a carbonate —O—C(O)—O— group, a carbamate —O—C(O)—NH— group, an oxygen atom, a phosphate group, a phosphonate group or a heteroaryl group comprising 1 to 4 nitrogen atoms, unsubstituted or substituted by a linear or branched, saturated or unsaturated C8-C30 hydrocarbon chain, wherein L1 and L2 are not simultaneously hydrogen,
- or also, L1 and L2, together, form a ketal group of formula
- or also L1 or L2 represents hydrogen, and the other represents a hydroxy group or a heteroaryl group comprising 1 to 4 nitrogen atoms, unsubstituted or substituted by a linear or branched C8-C30, alkyl chain,
- R1 and R2, identical or different, represent
- a linear or branched C8-C30 hydrocarbon chain, saturated or partially unsaturated, or
- a C8-C30 acyl chain,
- a diacyl chain in which each acyl chain is C8-C30,
- a diacylglycerol in which each acyl chain is C8-C30, or
- a sphingosine or ceramide group in which each acyl chain is C8-C30, or
- when L1 or L2 represents hydrogen, and the other represents a hydroxy group or a heteroaryl group comprising 1 to 4 nitrogen atoms, R1 and R2 do not exist;
- R3 represents
- a hydroxy, amino, phosphate, phosphonate, phosphatidylcholine, O-alkyl phosphatidylcholine, thiophosphate, phosphonium, NH2—R4, NHR4R5 or NR4R5R6 group in which R4, R5 and R6, identical or different, represent a hydrogen atom or a linear or branched C1-C6 alkyl chain or linear or branched C1-C6 hydroxyalkyl, or
- a linear or branched C2-C30 alkyl chain, optionally substituted by a hydroxy group, or
- a heteroaryl group containing 1 to 4 nitrogen atoms, unsubstituted or substituted by a C2-C30 alkyl, optionally substituted by a hydroxy group; or by a (CH2)m—O—(CH2)p—R9 group in which m=1 to 6 and p=0 to 20 and R9 represents hydrogen or a cyclic ketal group containing 5 to 7 carbon atoms, unsubsiituted or substituted by at least one linear or branched C2-C30 alkyl, or by a sterol radical, or
- a —O—C(O)—(CH2)q—C(O)—O[(Ch2)2—O]r—H group in which q is an integer from 2 to 6 and r is an integer from 4 to 30, preferably from 10 to 20, or also
- R3 is bound by a covalent bond to another substituent R3, identical or different, of another compound of formula (I), identical or different, in order to form a compound of formula (I) in the form of a dimer,
- b) at least one metal nanoparticle, and
- c) at least one therapeutic agent.
- The purine or pyrimidine base can be, for example, selected from, adenine, guanine, cytosine, xanthine, hypoxanthine, uric acid, caffeine, theobromine, uracile, thymine, dihydrouridine, and their derivatives.
- Thymine and uracile are preferred.
- Also, in formula (I) above, the purine or pyrimidine base can be substituted by at least one substituent selected from, for example, a halogen, an amino group, a carboxy group, a carbonyl group, a carbonylamino group, a hydroxy, azido, cyano, thiol, a C1-C6 straight or branched alkyl, cycloalkyl, perfluoroalkyl, alkyloxy (for example, methoxy), oxycarbonyl, vinyl, ethynyl, propynyl, acyl group etc.
- By “derivatives of a purine or pyrimidine base” is meant, for example, a non-natural mono- or bi-cyclic heterocyclic base in which each cycle has 4 to 7 members, optionally substituted as stated above for the purine or pyrimidine base.
- By «non-natural heterocyclic base» is meant a universal base, such as, for example, 3-nitropyrrole, 4-nitroimidazole or 5-nitroindole, which do not exist in nature.
- By «heteroaryl comprising 1 to 4 nitrogen atoms» is meant a mono- or bi-cyclic carbocyclic group, aromatic or partially unsaturated, comprising 5 to 12 atoms in total, interrupted by 1 to 4 nitrogen atoms, which can be, for example, selected from furane, pyrrole, oxazole, oxadiazole, isoxazole, pyrazole, triazole, tetrazole, imidazole, pyridine, pyrimidine, pyridazine, pyrazine, benzofurane, indole, quinoleine, isoquinoleine, chromane, naphtyridine and benzodiazine groups, triazole being preferred.
- The following compounds of formula (I), in which at least one condition is fulfilled, are preferred:
- X is an oxygen atom;
- B is thymine or uracile;
- L1 and L2 are oxycarbonyl —O—C(O)— groups which are substituted by a linear or branched C2-C30, preferably C8-C30, hydrocarbon chain, preferably C8-C26, more preferably C16-C20, saturated or partially unsaturated; or
- L1 is a phosphate group which is substituted by diacylglycerol in which each acyl group is C2-C30, preferably C8-C30, more preferably C8-C26, even more preferably C16-C20, and L2 is hydrogen;
- R3 is hydroxy, a NR4R5R6 group in which R4, R5 and R6 represent a hydrogen atom or a —O—C(O)—(CH2)q—C(O)—O[(CH2)2—O]r—H group in which q is an integer from 2 to 6 and r is an integer from 4 to 30, preferably from 10 to 20.
- Particularly preferred compounds of formula (I) are selected from
- N-[5′-(2′,3′-dioleoyl)uridine]-N′,N′,N′-trimethylammonium (DOTAU) (CAS Registry Number: 868226-06-6),
-
Thymidine 3′-(1,2-dipalmitoyl-sn-glycero-3-phosphate), also called diC16dT(CAS Registry Number: 1160002-70-9), and - Poly(oxy-1,2-ethanediyl), α-hydro-ω-methoxy-, ester with
uridine 5′-(hydrogen butanedioate) 2′,3′-di-(9Z)-9-octadecenoate (DOU-PEG) (CAS Registry Number: 1353570-75-8). - In a preferred embodiment, the lipid-based nanocarrier composition according to the invention comprises at least 2 different compounds of formula (I).
- In particular, the lipid-based nanocarrier composition can comprise at least one co-lipid in addition to the compound(s) of formula (I),
- By “co-lipid”, is meant a compound used in combination with the compound of formula (I), which contributes to the production of the structure of the lipid-based nanocarrier composition.
- Preferably, a zwitterionic co-lipid will be used.
- Said co-lipid can be, for example, chosen from dioleylphosphatidylcholine (DOPC), dioleylphosphatidyluridinephosphatidyl-choline (DOUPC) or dioleylphosphatidyleinanolamine (DOPE).
- These compounds can play the role of co-lipid when they are used in a mixture with a compound of formula (I). Alternatively, they can be included in formula (I), such as, for example, dioleylphosphatidyluridinephosphatidylcholine (DOUPC). In this case, they will either play the role of a compound of formula (I) or, in combination with another compound of formula (I), the role of co-lipid.
- For the preparation of the compounds of formula (I), reference can be made to WO 2005/116043, which describes different access routes to this type of compounds (see in particular pp. 8-17 and the examples), as well as to WO2009/098404 or WO 2010/136676.
- Preferably, the lipid-based nanocarrier composition according to the invention contains a plurality of metal nanoparticles, in particular 10 to 90% (w/w) of metal nanoparticles, preferably 50 to 80%.
- The metal nanoparticles contain, preferably, metal oxides which can be, for example, selected from iron oxide (magnetite Fe3O4, maghemite γ-Fe2O3, or other Co ferrite or Ni ferrite) which is known for its magnetic properties while metals (Au, Ag, Cu, Si, Ge, Fe, Co etc), metal alloys (FeCo, FePt, CoPt, FeBi etc.) and metal chalcogenides (CdS, CdSe, CdSe, ZnS . . . etc.) can be used for their plasmonic, luminescent or magnetic properties which are interesting in the aim to the development of a contrast agent or a labelling tool for bioimaging, tacking or sensoring.
- Preferably, the metal nanoparticles have an overall size (average diameter) of approximately from 2 nm to 20 nm, preferably 5 to 10 nm.
- The metal nanoparticles contained in the lipid-based nanocarrier compositions according to the invention may be mono-disperse (for example, they consist of a population having an average diameter centered around 10 nm), or mono- and/or poly-disperse (such as, for example, two populations having an average diameter centered around 4 nm and 10 nm), or else poly-disperse (different populations having different average diameters ranging from 2 nm and 20 nm).
- Iron oxide nanoparticles are preferred.
- The metal nanoparticles contained in the lipid-based nanocarrier compositions according to the invention can be, for instance, surface functionalized nanoparticles, or any type of nanoparticle presenting surface reactive groups, with a size comprised between 2 nm arid 20 nm, preferably 5 to 10 nm, having a surface modified by grafting of amphiphilic or fatty ligand composed of an anchoring function—mainly carboxylates, phosphonate groups used for metal oxide and amine, thiol functions or other strong nucleophilic functions for metal nanoparticles such as gold nanoparticles—and a hydrophobic moiety which could be saturated or unsaturated hydrocarbon chains or perfluorinated carbon chains.
- For example, coprecipited hydrophobic iron oxide nanoparticles have been prepared as previously published (G. A. van Ewijk, G. J. Vroege, A. P. Philipse, Convenient preparation methods for magnetic colloids, J. Magn. Magn. Mater. 201 (1999) 31-33) using stearic acid as fatty acid.
- In a preferred embodiment the metal nanoparticles have a surface functionalization which provides them with hydrophobic properties. For instance they bear fatty acid residues on their surface.
- By «therapeutic agent» is meant, for example, a natural or synthetic molecule used for preventing or treating a pathological condition, or restoring a biological function, in vitro or in vivo, in particular in animals, in particular in human beings, or else in isolated cells.
- Advantageously, said therapeutic agent can be selected, for example, from anti-tumoral agents, antibiotic agents, anti-microbial agents, analgesic agents, anti-histaminic agents, bronchodilators agents, agents which are active on the central nervous system, anti-hypertension agents or agents which are active on the cardiovascular system (in particular vasodilator agents, anti-atherosclerosis agents such as agents having a platelet anti-aggregating activity), nucleic acids and their fragments; peptides, oligopeptides, proteins, antigens, antibodies or else stem cells etc.
- Anti-cancer agents are of particular interest, such as, for example, sorafenib, sunitinib, taxanes (docetaxel, paclitaxel, cabazitaxel . . . ), doxorubicine, adriamycin, daunomycin, melphalan, gemcitabine, cisplatin, derivatives of gemcitabine, or derivative of cisplatin, imatinib (Gleevec®), 5-fluorouracil, 9-aminocamptothecin, amine-modified geldanamycin, Taxol®, procarbazine or hydroxyurea.
- Anti-atherosclerosis agents, such as, for example, tocopherols, resveratrol, anthocyanes, succinobucol, prostacycline, terutroban, picotamide, varespladib, darapladib, fumagilline, chemokins (CXCR3, IL10), aliskiren, lisinopril, losartan, irbesartan, telmisartan, epleronone, apolipoproteine A1 (APOA-1) or glutathion are also of particular interest.
- The invention also relates to a process for preparing a lipid-based nanocarrier composition comprising metal nanoparticles and at least one therapeutic agent, as described above, which comprises the following steps:
- preparing a solution containing at least one compound of formula (I), at least one metal nanoparticle and at least one therapeutic agent in an organic solvent
- adding this solution to an aqueous medium while stirring,
- sonicating the resulting aqueous solution and evaporating the organic solvent, and
- recovering the lipid-based nanocarrier composition thus obtained.
- Preferred reaction conditions are as follows:
- the organic solvent can be selected, for example, from ether, choloroform, methylene chloride, ethyl acetate, butanol, propanol, ethanol and methanol;
- the aqueous medium is water;
- the evaporation of the organic solvent is carried out under reduced pressure, namely, for example, the pressure is reduced from 1 bar to 5 mbar;
- the lipid-based nanocarrier composition is recovered by centrifugation, for example at 14000 rpm during 15 to 30 min.
- After centrifugation, the pellet containing the lipid-based nanocarrier composition may be re-suspended in water.
- Preferably, when contained in the lipid-based nanocarrier compositions according to the invention as defined above, the therapeutic agent will be present at a concentration of about of 0.1 ng/mL to 10 mg/mL, and metal nanoparticles at a concentration of about of 0.1 ng/mL to 10 mg/mL, in the aqueous phase.
- The invention also relates to the use of a lipid-based nanocarrier composition as an agent for transportation, vectorization, cellular delivery cellular targeting or cellular localization of at least one therapeutic agent, in particular for imaging guided therapy.
- For example, the lipid-based nanocarrier composition according to the invention may be used in various therapeutic fields relating to diseases and/or disorders such as cancers, atherosclerosis, viral and non-viral infections, immunity disorders, inflammation etc.
- The invention also concerns pharmaceutical compositions containing a lipid-based nanocarrier composition as described above and a pharmaceutically acceptable carrier.
- The invention is illustrated non-limitatively by the examples below.
- All commercially available reagents and solvents (Fluka, Sigma-Aldrich, Alfa-Aesar) were used without further purification.
- Column chromatography was performed with flash silica gel (0.04-0.063 mm, Merck) or LH20 size-exclusion column (Sephadex LH-20)
- The following abbreviations are used
- 1,2-Dioleyl-sn-Glycero-3-phosphocholine (DOPC) (CAS Registry Number: 4235-95-4)
- N[5′-(2′,3′-dioleoyl)uridine]-N′,N′,N′,-trimethylammonium (DOTAU) (CAS Registry Number: 868226-06-6)
-
Thymidine 3′-(1,2-dipalmitoyl-sn-glycero-3-phosphate) (also called diC16dT), CAS Registry Number: 1160002-70-9 and - Poly(oxy-1,2-ethanediyl), α-hydro-ω-methoxy-, ester with
uridine 5′-(hydrogen butanedioate) 2′,3′-di-(9Z)-9-octadecenoate (DOU-PEG) (CAS Registry Number: 1353570-75-8) -
FIG. 1 shows the size distribution by intensity measured by Dynamic Light Scattering (DLS) (FIG. 1A ) and the zeta potential distribution (FIG. 1B ) of DOTAU nanoparticles (control). -
FIG. 2 shows the size distribution by intensity measured by Dynamic Light Scattering (DLS) (FIG. 2A ) and the Zeta potential distribution (FIG. 2B ) of nanoparticles of diC16dT (control). -
FIG. 3 shows the size distribution by intensity measured by Dynamic Light Scattering (DLS) (FIG. 3A ) and the Zeta potential distribution (FIG. 3B ) of a lipid-based (DOTAU) nanocarrier composition containing α-tocopherol. -
FIG. 4 shows the size distribution by intensity measured by Dynamic Light Scattering (DLS) (FIG. 4A ) and the Zeta potential distribution (FIG. 4B ) of a lipid-based (diC16dT, DOPC (co-lipid) and DOU-PEG2000) nanocarrier composition containing prostacycline (PGl2.Na). -
FIG. 5 shows a SDS Page gel experiment of a lipid-based (DOTAU) nanocarrier composition containing Apolipoprotein-A1 (APOA1). -
FIG. 6 shows the size distribution by intensity measured by Dynamic Light Scattering (DLS) (FIG. 6A ) and the Zeta potential distribution (FIG. 6B ) of a lipid-based (DOTAU) nanocarrier composition containing Apolipoprotein-A1 (APOA1). -
FIG. 7 shows the particule size of iron oxide nanoparticles clusters encapsulated by DOTAU or diC16dT (preparations 1 and 2) or of a DOTAU-based nanocarrier composition comprising iron oxide nanoparticles and α-tocopherol (example 1) determined with a Zetasizer 3000 HAS MALVERN. -
FIG. 8 shows the detection standard curve for DOTAU (FIG. 8A ) and α-tocopherol (FIG. 8B ). -
FIG. 9 shows the HPLC analysis of iron oxide nanoparticles clusters encapsulated by DOTAU prepared inpreparation 1 and of a DOTAU-based nanocarrier composition comprising iron oxide nanoparticles and α-tocopherol prepared in example 1. -
FIG. 10 shows a stability comparison of iron oxide nanoparticles clusters encapsulated by a lipid (DOPC) or by a nucleolipid (DOTAU). -
FIG. 11 shows the Magnetic Resonance Relaxometry study of preparations of cationic or anionic metal nanoparticles. -
FIG. 12 shows the platelet anti-aggregating activity of the nanocarrier composition of example 2. - 100 μL of stock solution of positively charged nucleolipid (DOTAU), (50 mg/mL in ether) and 20 μL of stock solution of iron oxide nanoparticles (10 mg/mL in ether) were mixed. DOTAU was prepared according to P. Chabaud et al., Bioconjugate Chem., 2006, 17, 466-472. The organic phase was added dropwise into the aqueous phase (2 mL of Milli-Q Water) placed in glass tube under stirring by vortex. Then the mixture was placed in glass flask.
- Ether was removed under vacuum and the resulting crude material solution was sonicated for 3×15 min time and purified on LS columns to give pure solution of nanoparticles.
- The size distribution by intensity measured by Dynamic Light Scattering (DLS) (d=80 nm) and the Zeta potential distribution measured with a MalvernNanoZS device (Zeta potential=+55 mV) are shown on
FIGS. 1A and 1B . - PREPARATION 2: ENCAPSULATION OF IRON OXIDE NANOPARTICLES CLUSTERS BY diC16dT (CONTROL)
- 75 μL of stock solution of negatively charged nucleolipid (diC16dT) (50 mg/mL in chloroform), 25 μL of stock solution of 1,2-Dioleoyl-sn-Glycero-3-Phosphocholine (DOPC) (Avanti Polar lipids, 50 mg/mL in chloroform), 30 μL of stock solution of neutral nucleolipid (DOU-PEG2000) (10 mg/mL in chloroform) and 20 μL of stock solution of iron oxide nanoparticles (10 mg/mL in chloroform) were mixed. DIC16dT was prepared as disclosed in WO2010/13676. DOU-PEG2000 was prepared according to K. Oumzil et al., 2011, J. Control. Release, doi:10.1016/j. j conrel.2011.02.008.
- The organic phase was added dropwise into the aqueous phase (2 ml of Milli-Q Water) placed in glass tube under stirring by vortex. Then the mixture was placed in glass flask.
- Chloroform was removed under vacuum and the resulting crude material solution was sonicated for 3×15 min and purified on LS columns to give pure solution of nanoparticles.
- The size distribution by intensity measured by Dynamic Light Scattering (DLS) (d=92 nm) and the Zeta potential distribution measured with a MalvernNanoZS device (Zeta potential=−23.6 mV) are shown on
FIGS. 2A and 2B . - 100 μL of stock solution of positively charged nucleolipid (DOTAU) (50 mg/mL in ether), 10 μL of stock solution of α-tocopherol (Sigma Aldrich, 50 mg/mL in ether) and 20 μL of stock solution of iron oxide nanoparticles (10 mg/mL in ether) were mixed. The organic phase was added dropwise into the aqueous phase (2 mL of Milli-Q Water) placed in glass tube under stirring by vortex. Then the mixture was placed in glass flask.
- Ether was removed under vacuum and the resulting crude material solution was sonicated for 3×15 min and purified on LS columns to give pure solution of nanoparticles.
- The size distribution by intensity measured by Dynamic Light Scattering (DLS) (d=108 nm) and the Zeta potential distribution measured with a MalvernNanoZS device (Zeta potential=+49,2 mV) are shown on
FIGS. 3A and 3B . - 75 μL of stock solution of negatively charged nucleolipid (diC16dT), (50 mg/mL in chloroform+2% Et3N), 25 μL of stock solution of DOPC as co-lipid (50 mg/mL in chloroform+2% Et3N), 30 μL of stock solution of neutral nucleolipid (DOU-PEG2000) (10 mg/mL in chloroform+2% Et3N), 1 mg of PGI2.Na (Sigma Aldrich) and 20 μL of stock solution of iron oxide nanoparticles (10 mg/mL in chloroform+2% Et3N) were mixed. The organic phase was added dropwise into the aqueous phase (2 ml of carbonate-bicarbonate buffer, pH 9.6 at 25 C.) placed in glass tube under stirring by vortex. Then the mixture was placed in glass flask.
- Chloroform was removed under vacuum and the resulting crude material solution was sonicated for 3×15 min and purified on LS column to give pure solution of nanoparticles.
- The size distribution by intensity measured by Dynamic Light Scattering (DLS) (d=154 nm) and the Zeta potential distribution measured with a MalvernNanoZS device (Zeta potential=+−22.6 my) are shown on
FIGS. 4A and 4B . - 100 μL of stock solution of positively charged nucleolipid (DOTAU) (50 mg/mL in ether) and 20 μL of stock solution of iron oxide nanoparticles (10 mg/mL in ether) were mixed. The organic phase was added dropwise into the aqueous phase (100 μg of APOA1 (Sigma Aldrich) in 2 ml of Milli-Q Water) placed in glass tube under stirring by vortex. Then the mixture was placed in glass flask. Ether was removed under vacuum and the resulting crude material solution was sonicated for 3×15 min and purified on magnetic LS columns to give pure solution of nanoparticles. To demonstrate the presence of the APOA1 protein in the nanoparticles a SDS Page gel experiment was realised. The gel shows that the protein is present in the nanoparticles (two experiments,
FIG. 5 ). - The size distribution by number measured by Dynamic Light Scattering (DLS) measured with a MalvernNanoZS device of APOA1 (d=5.01 nm) and of the lipid-based (DOTAU) nanocarrier composition containing APOA1 (d=105 nm) and the size distribution by number measured by intensity are shown on
FIGS. 6A and 6B . - Iron oxide nanoparticles clusters encapsulated by DOTAU or diC16dT (
preparations 1 and 2) and DOTAU-based nanocarrier composition comprising iron oxide nanoparticles and α-tocopherol (example 1) in 500 μL of Milli-Q water were incubated at 37° C. under a 506 rpm stirring. For different times (0, 1, 3, 6, 24, 48 h), particle sizes were determined using a Zetasizer 3000 HAS MALVERN. - The results are shown on
FIG. 7 . - The results show that the overall sizes, either in absence or presence of therapeutic agents, and either positively or negatively charged, are not modified as a function of time (more than 2 days), which indicates colloidal stability both at room temperature and at 37° C.
- Pure suspensions of cationic nanoparticles prepared in
preparation 1 and example 1 were centrifuged at 14000 rpm for 15 min in order to remove the supernatant. Cationic nanoparticles (in the form of pellet) were suspended in ethanol. The resulting solution was mixed for 15 min at RT and centrifuged at 14000 rpm for 5 min. Then the supernatant (ethanol) was analyzed by HPLC. - A reverse phase U-HPLC method was developed for nucleolipid (DOTAU) and α-tocopherol quantification from the lipid-based nanocarrier composition containing iron oxide nanoparticles. This method allows the separation of the DOTAU and lipid-based (DOTAU) nanocarrier composition within 5 min.
- The separation was carried out with a
column Syncronis C18 50×2.1 mm, 1.7 μm with a mobile phase composed of MeOH+0.1% HCOOH. The flow rate was set to 0.2 mL/min. The detection was performed at 293 nm and 260 nm for α-tocopherol and DOTAU, respectively. The injected volume was 1.0 μL, which allows the detection of DOTAU and α-tocopherol at thresholds of 5 ng and 15 ng, respectively. - Standard curves for DOTAU and α-tocopherol, as shown on
FIGS. 8A and 8B , were generated by determining the intensity of signal versus concentrations. - The HPLC analysis is shown on
FIGS. 9A (260 nm) and 9B (293 nm). - Quantification of both DOTAU and α-tocopherol was then possible, which led to encapsulated recovery and determination of loading ratio values. Loading ratio was 38% that obtained in the case of a DOTAU/α-tocopherol (example 1) and the encapsulated drug recovery was around 10%, as shown in Table 1 below.
-
TABLE 1 Mass in the Mass in supernatant the pellet Loading Recovery Sample No Molecule (mg) (mg) ratio ratio 1 DOTAU 2.80 0.12 5 mg 2 DOTAU 4.02 0.12 30% 10% 5 mg alpha- 0.52 0.05 tocopherol 0.5 mg 3 DOTAU 3.61 0.11 38% 6% 5 mg alpha- 0.93 0.06 tocopherol 1 mg - This method has the advantage of using a low amount for analysis and a short analysis time, and has compatibility with mass spectrometry, which can be useful for biological analysis.
- In order to show the role of nucleolipids of formula (I) in the stabilisation of encapsulated metal nanoparticles, a control experiment was achieved with DiOleylPhosphatidylCholine (DOPC) only, in the absence of nucleolipid.
- 75 μL of stock solution of (DOPC) (Avanti Polar ipids, 50 mg/mL in chloroform) and 20 μL of stock solution of iron oxide nanoparticles (10 mg/mL in chloroform) were mixed. The organic phase was added dropwise into the aqueous phase (2 ml of Milli-Q Water) placed in glass tube under stirring by vortex. Then the mixture was placed in a glass flask. Chloroform was removed under vacuum and the resulting crude material solution was sonicated 3 times (3×15 minutes) to give a precipitate.
- The same protocol was followed, except that the nucleolipid N-[5′-(2′,3′-dioleoyl)uridine]-N′,N′,N′-trimethylammonium (DOTAU) was used instead of DOPC. The sonication did not give a precipitate.
- The photographs of
FIG. 10 show that the nucleolipid DOTAU allows the formation of a stable colloïdal suspension (photograph A), whereas in similar conditions with the lipid DOPC a precipitate is formed, which evidences that DOPC does not provide this colloidal stabilization (photograph B). - A total number of 8 different concentrations ranging from 0 to 0.5 mM Fe of iron oxide nanoparticles clusters encapsulated by DOTAU or diC16dT (
preparations 1 and 2) were prepared in Eppendorf PCR Tubes (0.5 mL). - Transverse images passing through the 8 tubes were acquired on a 4.7 T Bruker Biospin (Billerica, Mass.) magnetic resonance imaging (MRI) system with a 1 H whole body radiofrequency (RF) volume coil of 35 mm inner diameter and the relaxation rate (Rn) maps were computed using the Paravision 6.0 software. Samples were scanned at 21° C. with a 256×192 matrix and a field of view (FOV)=40×30 mm. R1 measurements were acquired using the Bruker T1 map Rapid Acquisition with Relaxation Enhancement (RARE) method (Repetition time (TR)=5000, 3000, 1500, 800, 400, 200 ms; Echo time (TE)=6 ms; RARE factor=2).
- Multi-spin-echo (ΔTE=8.45; number of echoes=20; TR=2 s) and gradient-echo (flip angle=60°; number of echo=8; TE initial=3.5 ms; ΔTE=5 ms; TR=800 ms; flyback) sequences were employed to compute an R2 map and R2*map, respectively. The mean relaxation rates, Rn, of each dilution were calculated from regions of interest (ROIs) encompassing each tube and plotted versus their corresponding Fe concentrations.
- A linear regression was used to extract the relaxivity (rn) of each sample, given as the slope of the resulting line in units of s−1 mM−1 of Fe, as shown on
FIG. 11 . - The results show that the iron oxide nanoparticles clusters encapsulated by DOTAU (represented by the line with x signs) or diC16dT (represented by the line with • signs), have improved magnetic properties in comparison to contrast agents commonly used in the medical field, such as Feridex® (dotted line). Feridex particles® are described in D. Patel et al., Biomaterials, 2011, 32, 1167-1176.
- Accordingly, the iron oxide nanoparticles clusters encapsulated by either cationic or anionic nucleolipids of formula (I) (
preparations 1 and 2), which are part of the lipid based-nanocarrier composition of the invention, allow an improved MRI detection, due to an increased sensitivity for the imaging system. - These results were published in K. Oumzil et al., Bioconjugate Chem., 2016, 27, 569-575.
- Blood was obtained in 1/10th volume of 3.8% sodium citrate from healthy volunteers who had not taken any drugs known to affect platelet function for 2 weeks prior to the study. Platelet rich plasma (PRP) was prepared by centrifugation at 20° C. for 10-15 min at 150-200 g and stored at room temperature.
- Platelet-poor plasma (PPP) was prepared by further centrifugation of the remaining plasma at 2700 g for 15 min and was used to calibrate the 100% light transmission of the aggregometer.
- The percentage of aggregation was followed versus time. PRP (207 μL) was stirred in cuvette at 37° C. and agonists adenosine 5′-diphosphate (ADP) or thrombin receptor-activating peptide -6 (TRAP-6) were added at 5 s to promote platelet aggregation, and was incubated either with the DOU-PEG2000-based nanocarrier composition containing iron oxide nanoparticles and prostacyclin (PGI2) of example 2, or with the iron oxide nanoparticles clusters encapsulated by diC16dT of preparation 2 (used as negative control) or with the agonist(s) only (negative control) or with the agonist(s) and PGI2 (positive control) for 15 min and 3 h for evaluating PGI2 activity. The in vitro platelet aggregation was determined using a four-channel light transmission aggregometer (APACT 4004, ELITech, France).
- The results are shown on
FIG. 12 , where the curves numbered 1 to 7 represent the following experimental conditions: -
PRP+TRAP-6 Curve No. 1 -
PRP+ADP+preparation 2 Curve No. 2 -
PRP+ADP Curve No. 3 -
PRP+TRAP−6+example 2 (3 h incubation) Curve No. 4 -
PRP+TRAP−6+PGI2 Curve No.5 -
PRP+ADP+PGI2 Curve No.6 -
PRP+ADP+example 2 (15 min incubation) Curve No.7 - The results show that the DOU-PEG2000-based nanocarrier composition containing iron oxide nanoparticles and PGI2 of example 2 as well as free PGI2 totally inhibit the platelet aggregation induced by both ADP (15 min incubation) and TRAP-6 (3 h incubation) agonist, whereas the iron oxide nanoparticles clusters encapsulated by diC16dT of
preparation 2, used as negative control (curve No.2), show complete ADP aggregation. - These results were published in K. Oumzil et al., Bioconjugate Chem., 2016, 27, 569-575.
Claims (16)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP15305592.6 | 2015-04-20 | ||
EP15305592.6A EP3085360A1 (en) | 2015-04-20 | 2015-04-20 | Lipid based nanocarrier compositions loaded with metal nanoparticles and therapeutic agent |
PCT/EP2016/058805 WO2016170010A1 (en) | 2015-04-20 | 2016-04-20 | Lipid based nanocarrier compositions loaded with metal nanoparticles and therapeutic agent |
Publications (1)
Publication Number | Publication Date |
---|---|
US20180116972A1 true US20180116972A1 (en) | 2018-05-03 |
Family
ID=52998003
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US15/567,628 Abandoned US20180116972A1 (en) | 2015-04-20 | 2016-04-20 | Lipid based nanocarrier compositions loaded with metal nanoparticles and therapeutic agent |
Country Status (5)
Country | Link |
---|---|
US (1) | US20180116972A1 (en) |
EP (2) | EP3085360A1 (en) |
JP (1) | JP2018513195A (en) |
CA (1) | CA2983079A1 (en) |
WO (1) | WO2016170010A1 (en) |
Families Citing this family (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP3502684A1 (en) | 2017-12-22 | 2019-06-26 | Universite De Bordeaux | Method for metal ion detection in aqueous solutions using nucleolipid compounds |
FR3078064A1 (en) | 2018-02-22 | 2019-08-23 | Universite de Bordeaux | PROCESS FOR DECONTAMINATING AN AQUEOUS LIQUID MEDIUM CONTAINING MICROPOLLUTANTS |
IL293592A (en) | 2019-12-06 | 2022-08-01 | Vertex Pharma | Substituted tetrahydrofurans as modulators of sodium channels |
WO2022194926A1 (en) * | 2021-03-17 | 2022-09-22 | Institut National De La Sante Et De La Recherche Medicale (Inserm) | Nanoparticles comprising a core with a phenazine derivative and a shell with a nucleolipid and uses thereof |
AU2022284886A1 (en) | 2021-06-04 | 2023-11-30 | Vertex Pharmaceuticals Incorporated | N-(hydroxyalkyl (hetero)aryl) tetrahydrofuran carboxamides as modulators of sodium channels |
Family Cites Families (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR2869616B1 (en) | 2004-04-29 | 2008-10-24 | Univ D Avignon Et Des Pays Du | NOVEL AMPHIPHILIC COMPOUNDS, PROCESS FOR THEIR PREPARATION AND THEIR APPLICATIONS IN PARTICULAR FOR TRANSFECTION |
FR2924430B1 (en) | 2007-11-30 | 2010-03-19 | Univ Bordeaux 2 | PROCESS FOR THE PREPARATION OF NANOPARTICLES BASED ON FUNCTIONAL AMPHIPHILIC MOLECULES OR MACROMOLECULES AND THEIR USE |
JPWO2010013676A1 (en) | 2008-07-28 | 2012-01-12 | 出光興産株式会社 | Organic light-emitting medium and organic EL device |
FR2945946B1 (en) | 2009-05-29 | 2011-08-26 | Univ Victor Segalen Bordeaux 2 | MULTI-COMPARTMENT FORMULATIONS BASED ON FUNCTIONAL AMPHIPHILIC MOLECULES OR MACROMOLECULES |
WO2013019137A1 (en) * | 2011-08-04 | 2013-02-07 | Institution Of The Russian Academy Of Sciences Tomsk Scientific Center, Siberian Branch, Russian Academy Of Sciences | Oxide ferrimagnetics with spinel structure nanoparticles and iron oxide nanoparticles, biocompatible aqueous colloidal systems comprising nanoparticles, ferriliposomes, and uses thereof |
US20140271470A1 (en) * | 2013-03-13 | 2014-09-18 | Laurel O. Sillerud | Targeted theranostics for metastatic prostate cancer |
-
2015
- 2015-04-20 EP EP15305592.6A patent/EP3085360A1/en not_active Withdrawn
-
2016
- 2016-04-20 EP EP16718316.9A patent/EP3285741A1/en not_active Withdrawn
- 2016-04-20 US US15/567,628 patent/US20180116972A1/en not_active Abandoned
- 2016-04-20 JP JP2017555589A patent/JP2018513195A/en active Pending
- 2016-04-20 WO PCT/EP2016/058805 patent/WO2016170010A1/en active Application Filing
- 2016-04-20 CA CA2983079A patent/CA2983079A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
CA2983079A1 (en) | 2016-10-27 |
JP2018513195A (en) | 2018-05-24 |
EP3285741A1 (en) | 2018-02-28 |
EP3085360A1 (en) | 2016-10-26 |
WO2016170010A1 (en) | 2016-10-27 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US20180116972A1 (en) | Lipid based nanocarrier compositions loaded with metal nanoparticles and therapeutic agent | |
Tang et al. | Emerging blood–brain-barrier-crossing nanotechnology for brain cancer theranostics | |
JP6932389B2 (en) | Targeted conjugate and its particles and formulations | |
ES2776100T3 (en) | System for targeted delivery of therapeutic agents | |
Fang et al. | Lipid-insertion enables targeting functionalization of erythrocyte membrane-cloaked nanoparticles | |
Zhang et al. | Surface engineering of nanomaterials with phospholipid-polyethylene glycol-derived functional conjugates for molecular imaging and targeted therapy | |
Tian et al. | Folic acid-targeted etoposide cubosomes for theranostic application of cancer cell imaging and therapy | |
Wang et al. | Magnetically and pH dual responsive dendrosomes for tumor accumulation enhanced folate-targeted hybrid drug delivery | |
Gao et al. | Nanomedicines guided nanoimaging probes and nanotherapeutics for early detection of lung cancer and abolishing pulmonary metastasis: critical appraisal of newer developments and challenges to clinical transition | |
US20140314864A1 (en) | System for Targeted Delivery of Therapeutic Agents | |
JP6347850B2 (en) | Dual-purpose PAT / ultrasound contrast agent to which drug-containing nanoparticles are bound and method for producing the same | |
US20210252171A1 (en) | Magnetic nanoparticles functionalized with catechol, production and use thereof | |
Xu et al. | RVG-functionalized reduction sensitive micelles for the effective accumulation of doxorubicin in brain | |
JP7390665B2 (en) | Nanosystems as selective vehicles | |
Khoshnood et al. | N doped-carbon quantum dots with ultra-high quantum yield photoluminescent property conjugated with folic acid for targeted drug delivery and bioimaging applications | |
Shen et al. | Combo-targeted nanoassemblies as a chemotherapy delivery system against peritoneal carcinomatosis colorectal cancer | |
US10537531B2 (en) | Casein coated drug-loaded iron oxide nanoparticles | |
Wang et al. | Optimization of landscape phage fusion protein-modified polymeric PEG-PE micelles for improved breast cancer cell targeting | |
KR101435261B1 (en) | Anticancer Agent-Linker-Albumin Conjugate, Preparation Method Thereof and Drug Delivery Composition Comprising the Conjugate | |
Tarin et al. | Targeted delivery of elesclomol using a magnetic mesoporous platform improves prostate cancer treatment both in vitro and in vivo | |
JP6412676B2 (en) | Nanoparticles and nanoparticle formulations | |
CN117982460A (en) | Preparation and application of spherical rod-shaped lipid nano particles | |
WO2021242933A1 (en) | Monocyte-specific aptamers and uses thereof for enhancing drug delivery to cancer | |
CN115089726A (en) | Tumor targeted diagnosis and treatment probe and preparation method and application thereof | |
CN117653613A (en) | Psoralen polymer lipid hybridization nanoparticle |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AS | Assignment |
Owner name: UNIVERSITE DE BORDEAUX, FRANCE Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:BARTHELEMY, PHILIPPE;OUMZIL, KHALID;CLOFENT-SANCHE, GISELE;AND OTHERS;SIGNING DATES FROM 20160718 TO 20160725;REEL/FRAME:044378/0027 Owner name: CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:BARTHELEMY, PHILIPPE;OUMZIL, KHALID;CLOFENT-SANCHE, GISELE;AND OTHERS;SIGNING DATES FROM 20160718 TO 20160725;REEL/FRAME:044378/0027 Owner name: INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE M Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:BARTHELEMY, PHILIPPE;OUMZIL, KHALID;CLOFENT-SANCHE, GISELE;AND OTHERS;SIGNING DATES FROM 20160718 TO 20160725;REEL/FRAME:044378/0027 Owner name: INSTITUT POLYTECHNIQUE DE BORDEAUX (IPB), FRANCE Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:BARTHELEMY, PHILIPPE;OUMZIL, KHALID;CLOFENT-SANCHE, GISELE;AND OTHERS;SIGNING DATES FROM 20160718 TO 20160725;REEL/FRAME:044378/0027 |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: NON FINAL ACTION MAILED |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: RESPONSE TO NON-FINAL OFFICE ACTION ENTERED AND FORWARDED TO EXAMINER |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: FINAL REJECTION MAILED |
|
STCB | Information on status: application discontinuation |
Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION |